Interleukin-5 binding protein dosage regimen for use in the treatment of polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (CRSWNP) or chronic rhinosinusitis without nasal polyps (CRSSNP)

A novel IL-5 binding protein treatment administered every 6 months effectively reduces eosinophil counts and alleviates symptoms of IL-5 mediated diseases like asthma and chronic sinusitis, addressing the need for reduced dosing profiles in current treatments.

JP2024542777APending Publication Date: 2024-11-15GLAXOSMITHKLINE INTPROP DEV LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024532973
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-06-07
Filing Date
2022-12-01
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

There is a need for more effective treatments for IL-5 mediated diseases such as asthma and chronic sinusitis with reduced dosing profiles, as current treatments are not sufficient in managing eosinophilic inflammation and exacerbations.

Method used

A pharmaceutical composition comprising antigen binding proteins that bind to IL-5, administered at doses of 100 mg to 300 mg every 6 months, utilizing a specific amino acid sequence and Fc domain linkage, to treat IL-5 mediated diseases.

Benefits of technology

The treatment effectively reduces eosinophil counts and alleviates symptoms of IL-5 mediated diseases, providing a less burdensome dosing regimen with improved patient compliance and therapeutic efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542777000013
    Figure 2024542777000013
  • Figure 2024542777000014
    Figure 2024542777000014
  • Figure 2024542777000015
    Figure 2024542777000015
Patent Text Reader

Abstract

The present disclosure relates to pharmaceutical compositions comprising about 100 mg to about 300 mg of an antigen-binding protein that binds to IL-5. The compositions and antigen-binding proteins of the present disclosure are useful for treating IL-5 mediated diseases such as EGPA, HES, CRSsNP and CRSwNP, and can be administered about once every six months.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to pharmaceutical compositions comprising antigen binding proteins (e.g., antibodies) that bind to IL-5 in novel doses and dosing regimens. In particular, the present invention relates to the use of antigen binding proteins (e.g., antibodies) that bind to IL-5 or pharmaceutical compositions comprising said antigen binding proteins in novel doses and dosing regimens for the treatment of IL-5 mediated diseases. The present invention is further directed to antigen binding proteins or pharmaceutical compositions comprising said antigen binding proteins for use in the treatment of IL-5 mediated diseases with said novel doses or dosing regimens. The present invention further relates to methods of treating IL-5 mediated diseases by administering antigen binding proteins (e.g., antibodies) that bind to IL-5 or pharmaceutical compositions comprising said antigen binding proteins under novel doses and dosing regimens. [Background technology]

[0002] Asthma is a chronic, heterogeneous lung disease characterized by inflammation, narrowing of the airways, and reversible airway obstruction. Patients with uncontrolled asthma suffer from ongoing symptoms and acute exacerbations of the disease. Exacerbations are particularly disabling and therefore require treatment of patients, usually with oral / systemic corticosteroids. The frequency of asthma exacerbations appears to be closely related to eosinophilic airway inflammation (FitzGerald & Gibson, Prevention. Thorax. 2006;61:992-999).

[0003] Persistent eosinophilic inflammation is a feature of more than 50% of patients with severe asthma (Chung et al., Eur. Respir. J., 2014;43:343-73). Several monoclonal antibodies targeting eosinophilic inflammation have received marketing authorization for asthma with an eosinophilic phenotype, including three that target either interleukin-5 (IL-5) or its receptor (IL-5R): mepolizumab (Nucala), reslizumab (Cinqair), and benralizumab (Fasenra). All three have been shown to reduce asthma exacerbations and improve lung function and health-related quality of life in patients with asthma with an eosinophilic phenotype by utilizing blood eosinophils as a biomarker to predict patients who are likely to respond to treatment.

[0004] IL-5 is a secreted protein. IL-5 plays a role in many different diseases, such as asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, subeosinophilic asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), nasal polyposis (NP), bullous pemphigoid, eosinophilic esophagitis, atopic dermatitis, moderate atopic dermatitis and severe atopic dermatitis, as well as chronic rhinosinusitis with nasal polyps (CRSwNP), inflammatory bowel disease (IBD), as well as allergic bronchopulmonary aspergillosis (ABPA), and chronic rhinosinusitis without nasal polyps (CRSsNP). These serious diseases affect hundreds of millions of people worldwide. Summary of the Invention [Problem to be solved by the invention]

[0005] In view of the above, it is clear that there is a need for more effective treatments for asthma. In particular, there is a need for effective treatments for IL-5 mediated diseases, such as eosinophilic asthma, that have a reduced dosage profile. [Means for solving the problem]

[0006] Thus, the present invention provides novel compositions, dosing regimens and methods of treatment suitable and effective with reduced dosing profiles for treating IL-5 mediated diseases such as asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma and subeosinophilic asthma, as well as inflammatory bowel disease (IBD), allergic bronchopulmonary aspergillosis (ABPA), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), nasal polyposis (NP), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis without nasal polyps (CRSsNP) and dermatitis.

[0007] In a first aspect, the present invention provides a pharmaceutical composition comprising about 100 mg to about 300 mg of an antigen-binding protein that binds to IL-5 and a pharma- ceutically acceptable excipient, the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The pharmaceutical composition further comprises a heavy chain Fc domain linked to the amino terminus of the heavy chain variable region.

[0008] In a further aspect, the present invention provides an antigen binding protein that binds IL-5 for use in treating an IL-5 mediated disease by administration to a subject at a dose of about 100 mg to about 300 mg about once every six months, comprising: the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The antigen binding protein is provided, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

[0009] In a further aspect, the present invention provides a pharmaceutical composition comprising about 100 mg to about 300 mg of an antigen binding protein that binds IL-5 for use in treating an IL-5 mediated disease, the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region; The pharmaceutical composition is provided, wherein the pharmaceutical composition is for administration to a subject about once every six months.

[0010] In a further aspect, the present invention provides a method of treating an IL-5 mediated disease, comprising: the method comprises administering to a subject in need thereof an antigen-binding protein that binds to IL-5 in an amount of about 100 mg to about 300 mg about once every six months; the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

[0011] In a further aspect, the present invention provides a method of treating an IL-5 mediated disease in a subject, comprising: The method further comprising: a) identifying a subject having a disease selected from the group consisting of asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, and subeosinophilic asthma; and b) administering to the subject an antigen-binding protein that binds to IL-5 in an amount of about 100 mg to about 300 mg about once every six months. thereby treating the disease in said subject, the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

[0012] In a further aspect, the present invention provides a method of reducing absolute blood eosinophil count in a subject, comprising: The method further comprising: a) identifying a subject having a condition selected from the group consisting of asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, subeosinophilic asthma; and b) administering to the subject an antigen-binding protein that binds to IL-5 in an amount of about 100 mg to about 300 mg about once every six months. thereby decreasing the absolute blood eosinophil count in said subject, the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

[0013] In a further aspect, the present invention provides a method for producing a method for the treatment of a cancer a) about 100 mg to about 300 mg of an antigen-binding protein that binds to IL-5, and b) Pharmaceutically acceptable excipients A prefilled syringe comprising: the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The pre-filled syringe is provided, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

[0014] In some embodiments, the pharmaceutical compositions disclosed herein comprise about 100 mg of an antigen binding protein disclosed herein. In some embodiments, the methods disclosed herein comprise administering about 100 mg of an antigen binding protein disclosed herein.

[0015] In some embodiments, the heavy chain variable region of the antigen binding protein further comprises the heavy chain FR4 amino acid sequence set forth in SEQ ID NO:19.

[0016] In some embodiments, the heavy chain Fc domain is an IgG1 Fc domain. In further embodiments, the heavy chain Fc domain is a human IgG1 Fc domain.

[0017] In some embodiments, the antigen binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4.

[0018] In some embodiments, the antigen binding protein is an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2.

[0019] In some embodiments, the pharmaceutical composition is for subcutaneous administration.

[0020] In some embodiments, the pharmaceutical composition is administered once every six months. In some embodiments, the pharmaceutical composition is administered once every 26 weeks (Q26W).

[0021] In some embodiments, the pharmaceutical composition is administered to a human subject.

[0022] In some embodiments, the subject (pre-treatment) has an absolute blood eosinophil count of 150 cells / μL or greater. In further embodiments, the subject (pre-treatment) has an absolute blood eosinophil count of 200 cells / μL or greater.

[0023] In a further embodiment, the subject has a blood glucose level of <10 mg / L -1 The patient may also have high sensitivity C-reactive protein (hsCRP).

[0024] In some embodiments, the pharmaceutical composition comprises an aqueous liquid formulation at about pH 6.0 comprising an antigen binding protein and histidine, trehalose, arginine, EDTA, and / or polysorbate 80. In some embodiments, the pharmaceutical composition comprises an aqueous liquid formulation at about pH 6.0 comprising an antigen binding protein and histidine, trehalose, arginine, EDTA, and polysorbate 80. In further embodiments, the pharmaceutical composition comprises an aqueous liquid formulation at about pH 6.0 comprising an antigen binding protein and about 20 mM histidine, about 180 mM trehalose, about 40 mM arginine, about 0.05 mM EDTA, and about 0.02% weight / volume polysorbate 80.

[0025] In some embodiments, the IL-5 mediated disease is asthma. In further embodiments, the asthma is selected from the group consisting of mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, poorly controlled eosinophilic asthma, eosinophilic asthma and subeosinophilic asthma. Preferably, the asthma is asthma with an eosinophilic phenotype (i.e. mild eosinophilic asthma, moderate eosinophilic asthma or severe eosinophilic asthma, in particular severe eosinophilic asthma). In further embodiments, the asthma is severe asthma.

[0026] In some embodiments, the IL-5 mediated disease is selected from inflammatory bowel disease (IBD), allergic bronchopulmonary aspergillosis (ABPA), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), nasal polyposis (NP), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis without nasal polyps (CRSsNP), and dermatitis. [Brief description of the drawings]

[0027] [Figure 1] Figure 1: Graphical summary of the study design. The planned single ascending subcutaneous (SC) doses of 28Y042-7F11-1 were 2, 10, 30, 100, and 300 mg. Actual dose levels beyond the starting dose of 2 mg were confirmed based on emerging data. Planned cohort sizes are shown; additional participants were to be added to cohorts if necessary to characterize the pharmacokinetics or pharmacodynamics of 28Y042-7F11-1. Within each cohort, participants were randomized 3:1 to receive 28Y042-7F11-1 or placebo. Additional cohorts of up to 12 participants were to be added to test additional dose levels or to repeat dose levels already tested if deemed necessary; however, doses were not to exceed 300 mg. The planned sample size was 48 participants, and the maximum sample size allowed was n = 72 participants (excluding replacements for participants who dropped out). [Diagram 2] Figure 2: Geometric means (and 95% CI) of blood eosinophil count (BEC) data (GI / L). Note: 95% confidence intervals (CI) are presented only when at least three participants contributed to the statistical analysis. [Diagram 3] Figure 3: Adjusted geometric means (and 95% CI) of ratios for baseline blood eosinophil data. Analyses were performed using an MMRM model on log-transformed data with fixed categorical effects of treatment, time point, and the interaction of treatment by time point, and fixed continuous covariates of log baseline blood eosinophil count and the interaction of log baseline blood eosinophil count by time point. The Teoplitz covariance structure was used. Note: The reference line at ratio = 0.22 indicates a 78% reduction from baseline, as observed in the phase 3b mepolizumab MUSCA trial. The reference line at ratio = 0.16 indicates an 84% reduction from baseline, as observed in the mepolizumab MENSA pivotal phase 3 trial. [Figure 4] Figure 4: Geometric means (and 95% CI) of serum total IL-5 data (ng / L). Values ​​below the lower limit of quantification (LLQ = 16.38 ng / L) were set to LLQ / 2. The LLQ is indicated by a horizontal reference line. Note: 95% CIs are only displayed when at least three participants contributed to the statistic and at least one value was not below the lower limit of quantification. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0028] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.

[0029] The term "antigen-binding polypeptide" as used herein refers to antibodies, antibody fragments and other protein constructs capable of binding to an antigen.

[0030] The term "antibody" is used herein in the broadest sense to refer to molecules having immunoglobulin-like domains (e.g., IgG, IgM, IgA, IgD or IgE) and includes monoclonal antibodies, recombinant antibodies, polyclonal antibodies, chimeric antibodies, human antibodies, humanized antibodies, multispecific antibodies, e.g., bispecific antibodies, and heteroconjugate antibodies; single variable domains (e.g., domain antibodies (DABs)), antigen-binding antibody fragments, Fab, F(ab')2, Fv, disulfide-linked Fv, single chain Fv, disulfide-linked scFv, diabodies, TANDABs, etc., as well as modified forms of any of the foregoing (for a review of alternative "antibody" formats, see Holliger and Hudson, Nature Biotechnology, 2005, Vol. 23, No. 9, pp. 1126-1136). Alternative antibody formats are also contemplated, including alternative scaffolds in which one or more CDRs of an antigen binding protein may be placed onto a suitable non-immunoglobulin protein scaffold or framework (e.g., an affibody, an SpA scaffold, an LDL receptor class A domain, an avimer, or an EGF domain, etc.).

[0031] Antibodies may be derived from rat, mouse, primate (e.g., cynomolgus monkey, Old World monkey or great ape), human or other sources (e.g., nucleic acids generated using molecular biology techniques that encode an antibody molecule).

[0032] The antibody may comprise a constant region, which may be of any isotype or subclass. The constant region may be of an IgG isotype, such as IgG1, IgG2, IgG3, IgG4, or variants thereof. The constant region of the antigen binding protein may be IgG1.

[0033] The antigen binding protein may include one or more modifications selected from a constant domain that has been mutated such that the antibody has enhanced effector function / ADCC and / or complement activation.

[0034] The term "antibody variant" as used herein means an antibody that differs from a parent antibody by at least one amino acid modification (e.g., by having a different amino acid side chain), by at least one post-translational or other modification in the heavy chain, light chain, or a combination thereof, resulting in a structural change (e.g., a different amino acid side chain, a different post-translational or other modification) compared to the parent antibody. Structural changes can be determined directly by a variety of methods well known in the art, such as LC-MS, direct sequencing, or indirectly through methods such as isoelectric focusing and similar methods. Such methods are well known to those of skill in the art.

[0035] In particular, an "antigen binding protein of the invention" as referred to herein refers to an antigen binding protein that binds to IL-5, said antigen binding protein comprising a heavy chain variable region having the CDRH1 amino acid sequence set forth in SEQ ID NO:5, the CDRH2 amino acid sequence set forth in SEQ ID NO:6, and the CDRH3 amino acid sequence set forth in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence set forth in SEQ ID NO:8, the CDRL2 amino acid sequence set forth in SEQ ID NO:9, and the CDRL3 amino acid sequence set forth in SEQ ID NO:10, and comprising a heavy chain Fc domain (e.g., IgG1 Fc) having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region, as well as any of the variants or specific embodiments of antigen binding proteins as described herein. The numbering of the amino acids in the heavy chain Fc domain (i.e., the tyrosine residue at position 252, the threonine residue at position 254, and the glutamic acid residue at position 256) was derived using EU numbering as described in Edelman et al., (1969) Proc. Natl. Acad. USA, 63:78-85 [PMID:5257969].

[0036] The antigen binding proteins of the invention can be used in any of the pharmaceutical compositions, dosing regimens or treatment methods of the invention. The antigen binding proteins of the invention can be antibodies, for example, IgG1 antibodies.

[0037] The term "about" or "approximately" means within an acceptable error range of a particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system.

[0038] For example, "about" may mean ±10%, as is customary in the art. Alternatively, "about" may mean within a range of ±20%, ±10%, ±5%, or ±1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term may mean within an order of magnitude, within 5-fold, or within 2-fold of a value. When specific values ​​are described in this application and claims, the term "about" is intended to mean within an acceptable range of error for the particular value, unless otherwise specified. Also, when ranges and / or subranges of values ​​are given, the ranges and / or subranges may include the endpoints of the ranges and / or subranges. The term "interleukin-5" or "IL-5" as used herein includes human IL-5 comprising the amino acid sequence set forth in SEQ ID NO:11. The term "interleukin-5 receptor" or "IL-5R" as used herein includes human IL-5R receptor subunit alpha isoform 1 comprising the amino acid sequence set forth in SEQ ID NO:12.

[0039] The term "specifically binds" as used herein in reference to an antigen binding protein means that the antigen binding protein binds to the target antigen, as well as to a distinct domain or distinct amino acid sequence within the target antigen, without or significantly without binding to other (e.g., unrelated) proteins. However, this term does not exclude the fact that the antigen binding protein may also have cross-reactivity with closely related molecules (e.g., molecules with a high degree of sequence identity or molecules from another genus or species). The antigen binding proteins described herein may bind to human IL-5 with an affinity that is at least 2-fold greater, 5-fold greater, 10-fold greater, 50-fold greater, 100-fold greater, or 1000-fold greater than it binds to closely related molecules.

[0040] The binding affinity (K D ) may be 1 mM or less, 100 nM or less, 10 nM or less, 2 nM or less, or 1 nM or less. D may be 5 nM to 10 nM or 1 nM to 2 nM. D The binding affinity of an antigen-binding protein may be expressed as an association constant (K a ) and the dissociation constant (K d ) and (K D =K d / K a ). Binding affinity can be measured by BIACORE™, for example, where the test antibody is captured on a Protein A coated sensor surface and the target antigen is flowed over the surface. Alternatively, binding affinity can be measured by FORTEBIO, for example, where the test antibody receptor is captured on a Protein A coated needle and the target antigen is flowed over the surface.

[0041] K d is 1 x 10 -3 Ms -1 Below, 1×10 -4 Ms -1 Less than or equal to 1×10 -5 Ms-1 It may be less than K. d is 1 x 10 -5 Ms -1 ~1×10 -4 Ms -1 Or 1×10 -4 Ms -1 ~1×10 -3 Ms -1 It may be slow K d may result in slow dissociation of the antigen-binding protein-target antigen complex and improved neutralization of the target antigen.

[0042] The term "specific antigen binding activity" as used herein means antigen binding activity as measured by surface plasmon resonance (SPR). IL-5 specific binding activity may be determined by SPR using a BIACORE™ instrument, for example, performed in binding mode. This is the binding activity divided by the total protein (e.g., 28Y042-7F11-1) content in the sample.

[0043] The term "FcRn binding activity" as used herein means neonatal Fc (FcRn) receptor binding activity as measured by surface plasmon resonance (SPR). FcRn binding may be determined using a BIACORE™ instrument. This is the binding activity to the FcRn receptor divided by the total protein concentration of the sample.

[0044] In the SPR method for specific antigen binding and FcRn binding, the reference standard of 28Y042-7F11-1 is used.The 28Y042-7F11-1 reference standard can be used in the assay to obtain the data of system suitability and sample comparability to ensure that the method is performed properly.The reference standard can allow the establishment of a calibration curve, and the concentration of the sample is interpolated from the curve.

[0045] By "isolated" is meant that a molecule, such as an antigen-binding protein, is removed from the environment in which it may be found in nature. For example, the molecule may be purified by removing it from materials with which it would normally be found in nature. For example, the amount of the molecule in a sample may be 95% of the total mass.

[0046] The terms "VH" and "VL" are used herein to refer to the heavy and light chain variable regions, respectively, of an antigen binding protein.

[0047] "CDR" is defined as the complementarity determining region amino acid sequence of an antigen-binding protein. It is the hypervariable region of the heavy and light chains of an immunoglobulin. Three heavy chain CDRs (or CDR regions) and three light chain CDRs (or CDR regions) are present in the variable portion of an immunoglobulin. Thus, "CDR" as used herein refers to all three heavy chain CDRs, all three light chain CDRs, all heavy chain CDRs and light chain CDRs, or at least one CDR, where at least one CDR is CDRH3. Each of these CDR regions is followed by a framework region. Acceptable framework 1, framework 2 and framework 3 regions of heavy and light chain variable regions are readily recognized by those skilled in the art. Acceptable heavy chain constant regions (including hinge regions) and light chain constant regions are also readily recognized by those skilled in the art. Acceptable antibody isotypes are also readily recognized by those skilled in the art.

[0048] Throughout this specification, amino acid residues in variable domain sequences and full-length antibody sequences are numbered according to the Kabat numbering convention. Similarly, the terms "CDR", "CDRL1", "CDRL2", "CDRL3", "CDRH1", "CDRH2", "CDRH3" as used herein follow the Kabat numbering convention.

[0049] It will be clear to those skilled in the art that there are alternative numbering conventions for amino acid residues in variable domain sequences and full-length antibody sequences. There are also alternative numbering conventions for CDR sequences. For example, CDR sequences are shown according to the Chothia numbering convention. The structure and protein folding of antibodies may mean that other residues are considered to be part of the CDR sequences and would be understood to be so by those skilled in the art.

[0050] Other numbering conventions for CDR sequences available to those skilled in the art include the "AbM" method (University of Bath) and the "contact" method (University College London). The minimum overlapping region using at least two of the Kabat, Chothia, AbM and contact methods can be determined to give a "minimal binding unit". The minimal binding unit may be a subpart of a CDR.

[0051] The term "asthma" as used herein refers to an inflammatory disease of the airways characterized by reversible airflow obstruction and bronchospasm. Common symptoms include wheezing, coughing, chest tightness and shortness of breath. Asthma is a heterogeneous disease usually characterized by chronic airway inflammation. Asthma is defined by a history of respiratory symptoms that vary over time and intensity, such as wheezing, shortness of breath, chest tightness and coughing, together with variable expiratory airflow limitation.

[0052] In the methods of the present invention, the diagnosis of asthma in a subject may be made according to the guidance provided by the Global Initiative for Asthma (GINA), Global Strategy for Asthma Management and Prevention (Updated 2016) document. Those skilled in the art are familiar with the GINA diagnosis flow chart for clinical practice and diagnostic criteria for asthma in adults, adolescent males and females, and children aged 6-11 years (Table 1), as well as other aspects of the guidance (e.g., for pregnant women, etc.). See also Tables 2 and 3.

[0053] [Table 1] JPEG2024542777000002.jpg103159

[0054] [Table 2]

[0055] [Table 3]

[0056] In the method of the present invention, "asthma" may be "mild asthma", "moderate asthma" or "severe asthma". In the method of the present invention, the severity of asthma may be evaluated according to GINA guidance. In particular, the severity of asthma may be evaluated retrospectively from the treatment level required to control symptoms and exacerbations. For example, the severity of asthma may be evaluated when a patient has been on controller treatment for several months and, if appropriate, a step-down of treatment is attempted to find the patient's minimum effective treatment level. The severity of asthma is not a static feature and may change over months or years.

[0057] Asthma severity can be assessed when a patient is on routine controller treatment for several months: "Mild asthma" is asthma that is adequately controlled by step 1 or step 2 treatment (see figure 9 in WO2018215964), i.e. by reliever medication alone as needed or by low-intensity controller treatment, e.g. low doses of ICS, leukotriene receptor antagonists or chromones. "Moderate asthma" is asthma that is well controlled with step 3 treatment (see Figure 9 of WO2018215964), e.g. low dose ICS / LABA. "Severe asthma" is asthma that requires step 4 or step 5 treatment (see Figure 9 in WO2018215964), e.g. high doses of ICS / LABA to prevent asthma from becoming "uncontrolled", or that remains "uncontrolled" despite this treatment. Although many patients with uncontrolled asthma may be difficult to treat due to insufficient or inappropriate treatment, or due to persistent problems with adherence or comorbidities (e.g. sinusitis or obesity), the European Respiratory Society / American Thoracic Society Task Force on Severe Asthma considered that the definition of "severe asthma" should be revised for patients with refractory asthma and those with incomplete response to treatment of comorbidities. Table 4 may also be referred to during the evaluation of asthma severity.

[0058] [Table 4]

[0059] In the methods of the present invention, "asthma" may be "mild eosinophilic asthma", "moderate eosinophilic asthma" or "severe eosinophilic asthma".

[0060] "Mild eosinophilic asthma" is mild asthma with eosinophilic phenotype. For example, a subject with mild eosinophilic asthma may have mild asthma and blood eosinophils of 150 or more eosinophils per μL of blood in the past 12 months, 200 or more eosinophils per μL of blood in the past 12 months, 300 or more eosinophils per μL of blood in the past 12 months, or 350 or more eosinophils per μL of blood in the past 12 months.

[0061] "Moderate eosinophilic asthma" refers to moderate asthma with eosinophilic phenotype. For example, a subject with moderate eosinophilic asthma may have moderate asthma and blood eosinophils of 150 or more eosinophils per μL of blood in the past 12 months, 200 or more eosinophils per μL of blood in the past 12 months, 300 or more eosinophils per μL of blood in the past 12 months, or 350 or more eosinophils per μL of blood in the past 12 months.

[0062] "Severe eosinophilic asthma" is severe asthma with eosinophilic phenotype. For example, a subject with severe eosinophilic asthma may have severe asthma and blood eosinophils of 150 or more eosinophils per μL of blood in the past 12 months, 200 or more eosinophils per μL of blood in the past 12 months, 300 or more eosinophils per μL of blood in the past 12 months (preferred), or 350 or more eosinophils per μL of blood in the past 12 months.

[0063] A subject with severe eosinophilic asthma may also meet one or more of the criteria set forth in Table 5.

[0064] [Table 5]

[0065] Importantly, subjects with severe eosinophilic asthma by these criteria may have less than 150 eosinophils per μL of blood at the start of treatment.

[0066] The term "pharmaceutical composition," as used herein, means a composition suitable for administration to a patient.

[0067] The term "therapeutically effective amount," as used herein, means an amount of an agent (e.g., an antigen binding protein or pharmaceutical composition, etc.) that provides a therapeutic benefit in the treatment or management of one or more symptoms of the condition being treated (e.g., asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, and subeosinophilic asthma, etc.). Examples of such treatment or management of one or more symptoms of asthma, including asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma and subeosinophilic asthma, include: 1) reducing the frequency of asthma exacerbations; 2) shortening the time to first clinically significant exacerbation requiring oral or systemic corticosteroids, hospitalization, and / or emergency department (ED) visit; 3) reducing the frequency of exacerbations requiring hospitalization (including intubation and intensive care unit transfer) or ED visit; 4) shortening the time to first exacerbation requiring hospitalization or ED visit; 5) change from baseline in clinical pre-bronchodilator FEV1; 6) change from baseline in clinical post-bronchodilator FEV1; 7) reducing the frequency of asthma exacerbations requiring hospitalization or ED visit; 8) improvement in pulmonary function as assessed by spirometry (e.g., vital capacity (VC) at set time intervals of 0.5, 1.0 (FEV1), 2.0, and 3.0 seconds, forced vital capacity (FVC), forced expiratory volume (FEV), forced expiratory flow rate at 25-75% (FEF25-75), and maximum ventilation (MVV), total lung capacity, idal volume, residual volume, expiratory reserve volume, inspiratory reserve volume, deep inspiratory volume, inspiratory capacity, vital capacity, functional residual capacity, residual volume expressed as a percentage of total lung capacity, alveolar gas volume, actual volume of the lung including volume of conducting airways, forced vital capacity, etc.); and 9) reduction in asthma exacerbations requiring steroids for control (e.g., oral steroids or steroids administered by any route, e.g., prednisone, prednisolone, etc.).Such a reduction in asthma exacerbations requiring steroids for control may be approximately a 50% reduction in exacerbations requiring steroids (eg, oral steroids).

[0068] Therapeutically effective amounts and treatment regimens are generally determined empirically and may depend on factors such as the age, weight, and health of the patient being treated, as well as the disease or disorder being treated. Such factors are within the purview of the attending physician.

[0069] As used herein, the term "treatment" refers to improving or stabilizing the specified condition, reducing or eliminating the symptoms of the condition, slowing or eliminating the progression of the condition, and preventing or delaying the recurrence of the condition in a previously affected patient or subject.

[0070] The methods, antigen binding proteins, and compositions of the present disclosure need not effect a complete cure or eradicate any symptoms or manifestations of the disease to constitute a viable therapeutic treatment. As recognized in the art, a drug used as a therapeutic in a treatment method may reduce the severity of a given disease state, but need not eliminate all manifestations of the disease to be considered a useful therapeutic. It is sufficient to merely reduce the impact of the disease (e.g., by reducing the number or severity of its symptoms, or by increasing the effectiveness of another treatment, or by producing another beneficial effect), or to reduce the likelihood that the disease will occur in a subject (e.g., by delaying the onset of the disease), or to reduce the likelihood that the disease will worsen in a subject.

[0071] As used herein, the term "subject" refers to a human body or an animal body. The terms "individual", "subject" and "patient" are used interchangeably herein. The subject is typically a human. The subject may also be a mammal, such as a mouse, rat or a primate (e.g., a marmoset or monkey). The subject may be a non-human animal. The antigen-binding proteins, compositions and methods of the present disclosure also have veterinary applications. The subject to be treated may be a farm animal, such as a cow or bull, sheep, pig, ox, goat or horse, or may be a domestic animal, such as a dog or cat. The animal may be of any age or may be a mature adult animal. The subject may be an adult subject (≧18 years old), or an adolescent subject (≧12 years old but less than 18 years old), or a pediatric subject (<12 years old). The subject may be between 6 years old and <18 years old.

[0072] In some embodiments, the subject described herein is a subject who has been switched from a treatment comprising an agent targeting IL-5 or IL-5R to a treatment comprising an antigen binding protein described herein. In some embodiments, the subject described herein is a subject who has been switched from a treatment comprising mepolizumab, reslizumab, or benralizumab to a treatment comprising an antigen binding protein described herein. In some embodiments, the subject described herein is a subject who is being treated with a non-biologic treatment comprising an agent targeting IL-5 or IL-5R. In some embodiments, the subject described herein is a subject who is being treated with a non-biologic treatment for asthma, for example, a corticosteroid and / or other controller, for example, a long-acting beta2-agonist (LABA) and / or a long-acting muscarinic antagonist (LAMA). The corticosteroid may be inhaled daily. In one embodiment, the subject described herein may be receiving a daily corticosteroid, such as fluticasone, e.g., by inhalation, e.g., the subject may be receiving a corticosteroid that is TRELEGY or RELVAR. In one embodiment, the subject may be receiving ≧440 micrograms of fluticasone propionate, or another such agent in a clinically comparable amount according to the GINA 2020 guidelines. In some embodiments, the subject described herein is a subject who has been switched from a treatment comprising an agent that targets IL-5 or IL-5R to a treatment comprising an antigen binding protein described herein, and who is being treated with a non-biologic treatment for asthma.In some embodiments, a subject described herein is a subject who has been switched from a treatment comprising an agent that targets IL-5 or IL-5R, e.g., mepolizumab, reslizumab, or benralizumab, to a treatment comprising an antigen binding protein described herein, and who is being treated with a non-biologic treatment for asthma, e.g., a corticosteroid and / or other controller, e.g., a long-acting beta2-agonist (LABA) and / or a long-acting muscarinic antagonist (LAMA). In some embodiments, the antigen binding protein is 28Y042-7F11-1.

[0073] In one embodiment, the subject being treated is receiving a maximum daily dose (μg) of a corticosteroid as follows: beclomethasone dipropionate (chorofluorocarbonate - CFC) = about 1000, beclomethasone dipropionate (hydrofluoroalkane propellant - HFA) = about 400, budesonide (DPI) = about 800, ciclesonide (HFA) = about 320, fluticasone propionate (dry powder inhaler - DPI) = about 500, fluticasone furoate (DPI) = about 100, mometasone furoate = about 440, triamcinolone acetonide = about 2000.

[0074] As used herein, the term "once every six months" means that in a typical six-month period of about 183 days, the subject is administered a dose of the antigen binding protein of the invention on only one day, and on the other days, the subject is not administered a dose of the antigen binding protein of the invention. Administration once every six months may also be referred to as "Q26W" (referring to administration once every 26 weeks). As referred to herein, "about once every six months" refers to an intended administration regimen of once every six months, but with tolerance for patient compliance and thus allowing for variations of up to four weeks depending on the patient's schedule.

[0075] For any type of range, the ranges set forth herein include all values ​​within the particular range stated, as well as values ​​near the endpoints of the particular range.

[0076] If desired, an effective dose of an antibody or antigen binding protein of the disclosure (e.g., as a pharmaceutical composition) may be administered as a unit dosage form. Administration of the dose may be by slow continuous infusion over a period of 2 to 24 hours, such as, for example, 2 to 12 hours or 2 to 6 hours. Such administration may result in reduced side effects.

[0077] Antigen-binding proteins The extended pharmacokinetic (PK) and pharmacological characteristics of the antigen binding protein described herein (28Y042-7F11-1) are achieved by reducing clearance and increasing affinity for IL-5, which are believed to allow for a single dosing every 26 weeks, as opposed to the current regimens of every 4 weeks for mepolizumab and reslizumab, or every 8 weeks for benralizumab (every 4 weeks for the first 3 doses).

[0078] Description of the invention In one aspect, the present invention provides an antigen binding protein that binds IL-5 for use in treating an IL-5 mediated disease, e.g., asthma (e.g., mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, subeosinophilic asthma), by administration to a subject in an amount of about 100 mg to about 300 mg about once every six months, the antigen binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence set forth in SEQ ID NO:5, the CDRH2 amino acid sequence set forth in SEQ ID NO:6, and the CDRH3 amino acid sequence set forth in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence set forth in SEQ ID NO:8, the CDRL2 amino acid sequence set forth in SEQ ID NO:9, and the CDRL3 amino acid sequence set forth in SEQ ID NO:10, and comprises a heavy chain Fc domain (e.g., IgG1 Fc) having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The antigen binding protein is provided, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region. In one embodiment, the heavy chain variable region of the antigen binding protein further comprises a heavy chain FR4 amino acid sequence as set forth in SEQ ID NO: 19.

[0079] The antigen-binding protein that binds to IL-5 comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain (e.g., IgG1 Fc) having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256, wherein the amino terminus of the heavy chain Fc domain is bound to the carboxy terminus of the heavy chain variable region. This antigen-binding protein that binds to IL-5 is a compound of the present invention and is disclosed in International Patent Application Publication No. WO2018215964.

[0080] In one embodiment, an antigen binding protein of the present invention is an antigen binding protein comprising a heavy chain variable region having the CDRH1 amino acid sequence set forth in SEQ ID NO:5, the CDRH2 amino acid sequence set forth in SEQ ID NO:6, and the CDRH3 amino acid sequence set forth in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence set forth in SEQ ID NO:8, the CDRL2 amino acid sequence set forth in SEQ ID NO:9, and the CDRL3 amino acid sequence set forth in SEQ ID NO:10, and comprising a heavy chain Fc domain (e.g., IgG1 Fc) having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region, wherein the antigen binding protein further comprises a heavy chain FR4 amino acid sequence set forth in SEQ ID NO:19.

[0081] In another embodiment, an antigen binding protein of the present invention comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4, and a heavy chain Fc domain (e.g., IgG1 Fc) having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region, wherein the antigen binding protein optionally further comprises a heavy chain FR4 amino acid sequence set forth in SEQ ID NO:19.

[0082] In one embodiment, the antigen binding protein of the present invention is an antibody comprising a heavy chain and a light chain, a) the heavy chain comprises a heavy chain variable region having a CDRH1 amino acid sequence set forth in SEQ ID NO:5, a CDRH2 amino acid sequence set forth in SEQ ID NO:6, and a CDRH3 amino acid sequence set forth in SEQ ID NO:7; b) The antibody, wherein the light chain comprises a light chain variable region having the CDRL1 amino acid sequence set forth in SEQ ID NO: 8, the CDRL2 amino acid sequence set forth in SEQ ID NO: 9, and the CDRL3 amino acid sequence set forth in SEQ ID NO: 10. The antibody may further comprise a heavy chain FR4 amino acid sequence set forth in SEQ ID NO: 19, and / or a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256. The heavy chain Fc domain may be an IgG1 Fc domain, for example a human IgG1 Fc domain.

[0083] In another embodiment, the antigen binding protein of the present invention is an antibody comprising a heavy chain and a light chain, a) the heavy chain comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3; b) The antibody, wherein the light chain comprises a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO: 4. The antibody can further comprise a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256. The heavy chain Fc domain can be an IgG1 Fc domain, e.g., a human IgG1 Fc domain.

[0084] In another embodiment, the antigen binding protein of the invention is an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2.

[0085] The antigen binding proteins of the invention may be variants of the above that retain the ability to bind IL-5, for example, useful variants may bind to human IL-5 with a binding affinity of at least about 10 pM as determined by KINEXA phase affinity analysis at about 25° C., or bind to human IL-5 with a binding affinity of at least about 30 pM (e.g., about 39 pM) as determined using a BIACORE T200 at about 37° C. Useful variants may also have a binding affinity to human FcRn of at least about 150 nM at pH 6.0 (determined at 37° C. using a BIACORE T200) and at least about 16100 nM at pH 7.4 (determined at 37° C. using a BIACORE T200). Useful variants may also have an improved half-life (PK) as determined in cynomolgus serum of at least about 20 days, e.g., about 24 days. For example, useful variants can include antibodies having at least about 90% identity to any of the sequences described herein, e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 98.5%, about 99%, about 99.5%, about 100% identity to any of the sequences described herein. For example, variants can include heavy chain variable region sequences having at least about 90% identity, e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 98.5%, about 99%, about 99.5%, about 100% identity to the amino acid sequence set forth in SEQ ID NO:3; and / or at least about 90% identity, e.g., about 91%, about 92% , about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 98.5%, about 99%, about 99.5%, about 100% identity to the heavy chain variable region sequence set forth in SEQ ID NO: 19, and may further comprise a heavy chain Fc domain (e.g., IgG1 Fc) having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

[0086] The variant may also be an antibody comprising a heavy chain having at least about 90% identity, e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 98.5%, about 99%, about 99.5%, about 100% identity, to the amino acid sequence set forth in SEQ ID NO:1, and a light chain having at least about 90% identity, e.g., about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 98.5%, about 99%, about 99.5%, about 100% identity, to the amino acid sequence set forth in SEQ ID NO:2.

[0087] In one embodiment, the invention provides an antibody that binds to IL-5 for use in treating asthma, e.g., eosinophilic asthma (e.g., moderate or severe eosinophilic asthma), by administration to a human subject at a dose of about 100 mg to about 300 mg approximately once every six months, the antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2.

[0088] 28Y042-7F11-1, which comprises the heavy chain amino acid sequence shown in SEQ ID NO: 1 and the light chain amino acid sequence shown in SEQ ID NO: 2, is an example of an antibody of the invention. 28Y042-7F11-1, or an antigen binding protein of the disclosure, binds to and antagonizes the activity of human IL-5.

[0089] 28Y042-7F11-1 is a recombinant humanized monoclonal antibody (IgG1, kappa). 28Y042-7F11-1 has two light chains and two heavy chains.

[0090] The 28Y042-7F11-1 heavy chain variable region is encoded by the nucleic acid sequence shown in SEQ ID NO: 15. The 28Y042-7F11-1 light chain variable region is encoded by the nucleic acid sequence shown in SEQ ID NO: 16.

[0091] The 28Y042-7F11-1 full length heavy chain is encoded by the nucleic acid sequence set forth in SEQ ID NO: 17. The 28Y042-7F11-1 full length light chain is encoded by the nucleic acid sequence set forth in SEQ ID NO: 18. During production, the nucleic acid sequence may include a leader sequence, such that the 28Y042-7F11-1 full length heavy chain may be encoded by the nucleic acid sequence set forth in SEQ ID NO: 13 and the 28Y042-7F11-1 full length light chain may be encoded by the nucleic acid sequence set forth in SEQ ID NO: 14.

[0092] The heavy and light chains of 28Y042-7F11-1 are covalently linked by one disulfide bond, and the heavy chains are linked to each other by two disulfide bonds, making it a typical IgG molecule.

[0093] The antigen binding proteins described herein may be produced by any number of conventional techniques. For example, the antigen binding proteins may be expressed in and purified from recombinant expression systems. In one embodiment, the antigen binding proteins are produced by a method of culturing a host cell under conditions suitable for expression of a polypeptide comprising SEQ ID NO:1 and SEQ ID NO:2, and the composition is expressed, optionally purified, and optionally formulated into a pharmaceutical composition.

[0094] A number of different expression systems and purification regimes can be used to produce the compositions. In general, the host cell is transformed with a recombinant expression vector encoding the antibody. A wide range of host cells can be used, including eukaryotic cell lines of mammalian origin (e.g., CHO, Perc6, HEK293, HeLa, NS0). Suitable host cells include mammalian cells such as CHO (e.g., CHOK1 and CHO-DG44).

[0095] The host cell may be an isolated host cell. The host cell is not normally part of a multicellular organism (e.g., a plant or an animal). The host cell may be a non-human host cell.

[0096] Appropriate cloning and expression vectors and cloning methods for use with eukaryotic or mammalian cell hosts are known in the art.

[0097] The cells may be cultured under conditions that promote expression of the antigen-binding protein. For example, a production bioreactor is used to culture the cells. The volume of the production bioreactor may be (i) about 20,000 liters, about 10,000 liters; about 5,000 liters; about 2,000 liters; about 1,000 liters; or about 500 liters; or (ii) 500-20,000 liters; 500-10,000 liters; 500-5,000 liters; 1,000-10,000 liters; or 2,000-10,000 liters. For example, the cells may be cultured in the production bioreactor at a pH of about 6.75 to about pH 7.00. Alternatively, the cells may be cultured in the production bioreactor for about 12 days to about 18 days. Alternatively, the cells may be cultured in a production bioreactor at a pH of about 6.75 to about pH 7.00 for about 12 to about 18 days. This culture step may help to control, e.g., reduce, the levels of deamidated antibody variants.

[0098] The antigen-binding protein may be recovered and purified by conventional protein purification procedures. For example, the antigen-binding protein may be harvested directly from the culture medium. Harvesting of the cell culture fluid may be via clarification, e.g., centrifugation and / or depth filtration. Recovery of the antigen-binding protein is followed by purification to ensure sufficient purity.

[0099] Purification may involve one or more chromatography steps, such as one or more chromatography resin steps; and / or one or more filtration steps. For example, affinity chromatography using a resin, such as protein A, G, or L, may be used to purify the composition. Alternatively or in addition, an ion exchange resin, such as cation exchange, may be used to purify the antigen-binding protein. Alternatively or in addition, a hydrophobic interaction chromatography resin may be used to purify the antigen-binding protein. Alternatively, the purification steps include an affinity chromatography resin step, followed by a cation exchange resin step, followed by a hydrophobic interaction chromatography resin step.

[0100] For example, the harvest may be contacted with a Protein A resin. The solution containing the composition may be eluted from the Protein A resin and treated at pH 3.3-3.7 for 15-240 minutes. This Protein A resin step may help to control, e.g., reduce, the levels of aggregated antibody variants.

[0101] The solution containing the antigen binding protein may then be further clarified by depth filtration and / or double layer filtration.

[0102] Alternatively or additionally, an anion exchange resin may be used. The solution containing the antigen binding protein may be contacted with a loading pH 8.3-8.7 anion exchange resin (e.g., Q-SEPHAROSE™ Fast Flow anion exchange chromatography). The solution containing the composition may be eluted from the anion exchange resin and held for up to 96 hours. This anion exchange resin step may help control the level of deamidated antibody variants, e.g., reduce the level of deamidated antibody variants.

[0103] Optionally, guanidine and / or ammonium sulfate may be added to the solution containing the composition and held for 15 to 240 minutes.

[0104] Alternatively or additionally, a hydrophobic interaction chromatography resin may be used. The solution containing the antigen-binding protein may be contacted with a hydrophobic interaction chromatography resin (e.g., SEPHAROSE™ fast flow chromatography) at a loading ratio of 12 to 27 g protein / L resin. For example, the solution containing the antigen-binding protein may be eluted using an elution gradient volume (bed volume; BV) of about 9 to about 11. During elution from the hydrophobic interaction chromatography resin, an elution peak cut stop (percentage of maximum peak height) of about 17 to about 23 may be used. This hydrophobic interaction chromatography resin step may help control the level of aggregated antibody variants, e.g., reduce the level of aggregated antibody variants.

[0105] Pharmaceutical Uses and Methods of Treatment Administration of an antigen-binding protein that binds IL-5 according to the present invention in an amount of about 100 mg to about 300 mg (e.g., 100 mg) at a frequency of about once every six months may provide a safe and effective therapy for the treatment of IL-5 mediated diseases, such as asthma (e.g., mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, poorly controlled eosinophilic asthma, eosinophilic asthma, subeosinophilic asthma). This administration strategy may also increase efficacy as a result of improved patient compliance, as patients only need to be dosed once every six months, thus resulting in a less burdensome regimen.

[0106] In one aspect, the invention provides a method of treating an IL-5 mediated disease, e.g., asthma (e.g., mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, subeosinophilic asthma), comprising: the method comprises administering to a subject in need thereof an antigen-binding protein that binds to IL-5 in an amount of about 100 mg to about 300 mg about once every six months; the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

[0107] In one embodiment, the IL-5 mediated disease is asthma. The asthma may be selected from the group consisting of mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, poorly controlled eosinophilic asthma, eosinophilic asthma and subeosinophilic asthma. In a further embodiment, the asthma has an eosinophilic phenotype, e.g., selected from mild eosinophilic asthma, moderate eosinophilic asthma or severe eosinophilic asthma. In one embodiment, the asthma is severe asthma.

[0108] The present invention also provides a method of treating asthma (e.g., mild, moderate or severe asthma, e.g., mild, moderate or severe eosinophilic asthma), comprising: the method comprising administering to a human subject in need thereof an antigen-binding protein that binds to IL-5 in an amount of about 100 mg to about 300 mg about once every six months; wherein the antigen binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4.

[0109] The present invention also provides a method of treating asthma (e.g., mild, moderate or severe asthma, e.g., mild, moderate or severe eosinophilic asthma), comprising: the method comprising administering to a human subject in need thereof an amount of about 100 mg to about 300 mg of an antibody that binds to IL-5 about once every six months; The antigen binding protein comprises a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2.

[0110] In one aspect, the present invention provides a method of treating an IL-5 mediated disease in a subject, comprising: The method further comprising: a) identifying a subject having a disease selected from the group consisting of asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, and subeosinophilic asthma; and b) administering to the subject about 100 mg to about 300 mg of an antigen-binding protein that binds to IL-5 at a frequency of about once every six months. thereby treating the disease in said subject, the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

[0111] In one embodiment, the IL-5 mediated disease is selected from inflammatory bowel disease (IBD), allergic bronchopulmonary aspergillosis (ABPA), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), nasal polyposis (NP), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis without nasal polyps (CRSsNP), and dermatitis. The disease may be characterized by an eosinophilic phenotype. The inflammatory bowel disease may be Crohn's disease or ulcerative colitis.

[0112] In one embodiment, there is provided a use of an antigen binding protein as described herein for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) by administration to a subject about once every six months, wherein the antigen binding protein is in an amount of about 100 mg.

[0113] In one embodiment, there is provided a use of an antigen binding protein as described herein for the treatment of chronic rhinosinusitis without nasal polyps (CRSsNP) by administration to a subject about once every six months, wherein the antigen binding protein is in an amount of about 100 mg.

[0114] The subject to be treated who has CRSwNP may have severe CRSwNP and / or may be undergoing treatment with SOC therapy, e.g., intranasal corticosteroids. Treatment with corticosteroids and / or surgery may not provide sufficient disease control.

[0115] Subjects to be treated with chronic rhinosinusitis without nasal polyps (CRSsNP) may have severe CRSsNP and / or may be undergoing treatment with standard of care (SOC), e.g., oral corticosteroids. Treatment with corticosteroids and / or surgery may not provide sufficient disease control. Chronic rhinosinusitis without nasal polyps (CRSsNP) is an inflammatory disease of the paranasal sinuses, characterized by fibrosis, basement membrane thickening, and goblet cell hyperplasia. Up to 50% of participants with CRSsNP subtypes in the United States have the type 2 inflammatory endotype, and pain is the main factor that reduces the quality of life of patients with CRSsNP. Fewer eosinophils are found in mucosal tissue in CRSsNP versus CRSwNP, but eosinophilic ("type 2") endotypes appear to be present. Activated eosinophils secrete numerous inflammatory mediators, including granule proteins, lipid mediators, cytokines, chemokines and growth factors, such as TGF-β, and their presence likely contributes to the pathological features present in CRSsNP. Thus, patients with CRSsNP treated according to the present invention may be type 2 or eosinophilic endotype with elevated nasal mucosal eosinophil levels, e.g., ≧150 cells / μL blood eosinophils, e.g., ≧300 cells / μL blood eosinophils.

[0116] In one embodiment, there is provided a use of an antigen binding protein as described herein for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) by administration to a subject about once every six months, wherein the antigen binding protein is in an amount of about 200 mg.

[0117] The subject with EGPA to be treated may have relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis. Treatment according to the invention may be in addition to other SOC treatments, such as oral corticosteroid (OCS) therapy with prednisolone / prednisone.

[0118] In one embodiment, there is provided a use of an antigen binding protein as described herein for the treatment of hypereosinophilic syndrome (HES) by administration to a subject about once every six months, wherein the antigen binding protein is in an amount of about 200 mg.

[0119] The subject with HES to be treated may have poorly controlled hypereosinophilic syndrome without identifiable non-hematological secondary causes.Treatment according to the invention may be in addition to other SOC treatments, such as oral corticosteroid (OCS) therapy with prednisolone / prednisone.

[0120] The current definition and diagnosis of HES uses the following criteria: 1. Blood eosinophilia >1500 eosinophils / μL on two separate tests (≥1 month apart) 2. Organ damage and / or dysfunction due to tissue eosinophilia; and 3. Exclusion of other diseases or conditions as the primary cause of organ damage.

[0121] A subject to be treated with HES may have a screening blood eosinophil count (as defined above) of >1500 eosinophils per μL, or a subject to be treated with HES may be a patient who has already been diagnosed with HES and has already received standard HES therapy, but still has a count of >1000 cells per μL.

[0122] If the dose administered is 200 mg (e.g., for HES or EGPA therapy), this may be contained in one unit or in several units (e.g., two units each containing 100 mg of active ingredient), each unit dose being administered separately, sequentially or simultaneously.

[0123] The subject treated as described herein may be an adult human subject (≧18 years old), or an adolescent subject (≧12 years old but less than 18 years old), or a pediatric subject (<12 years old). The subject may be 6 years old to <18 years old. In one embodiment, the dosages detailed herein are administered to adult subjects and also to subjects <18 years old but weighing 40 kg or more (e.g., pediatric / adolescent). For subjects <18 years old but weighing <40 kg, a flat dose approach is employed to get as close as possible to the target adult exposure based on the specific weight band.

[0124] In one aspect, the present invention provides a method of treating an IL-5 mediated disease in a subject, comprising: the method comprises administering to the subject about 100 mg to about 300 mg of an antigen-binding protein that binds to IL-5 about once every six months, thereby treating the disease in the subject; the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

[0125] As described herein, the heavy chain variable region of the antigen binding protein may further comprise a heavy chain FR4 amino acid sequence as set forth in SEQ ID NO: 19. In one embodiment, the heavy chain Fc domain is an IgG1 Fc domain. In a further embodiment, the heavy chain Fc domain is a human IgG1 Fc domain.

[0126] In one embodiment, the antigen binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO: 3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO: 4. In a further embodiment, the antigen binding protein is an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO: 1 and a light chain having the amino acid sequence set forth in SEQ ID NO: 2.

[0127] In one embodiment, the method comprises administering about 100 mg of the antigen binding protein.

[0128] In one embodiment, the method comprises administering the antigen binding protein subcutaneously.

[0129] In one embodiment, the subject is a human subject.

[0130] Preferably, the subject has (prior to treatment, e.g., at any time within the 12 months prior to treatment) an absolute blood eosinophil count of 100 cells per μL or greater, e.g., an absolute blood eosinophil count selected from the group consisting of 150 cells per μL or greater, 200 cells per μL or greater, 250 cells per μL or greater, 300 cells per μL or greater, or 350 cells per μL or greater.

[0131] In one embodiment, there is provided the use of an antigen binding protein as described herein in the manufacture of a medicament for administration about once every six months for the treatment of an IL-5 mediated disease, wherein the medicament comprises the antigen binding protein in an amount of about 100 mg to about 300 mg.

[0132] In another aspect, the present invention provides a method of reducing absolute blood eosinophil count in a subject, comprising: The method further comprising: a) identifying a subject having a condition selected from the group consisting of asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma and subeosinophilic asthma; and b) administering to the subject an antigen-binding protein that binds to IL-5 in an amount of about 100 mg to about 300 mg at a frequency of about once every six months. thereby decreasing the absolute blood eosinophil count in said subject, Including, the antigen binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence set forth in SEQ ID NO:5, the CDRH2 amino acid sequence set forth in SEQ ID NO:6, and the CDRH3 amino acid sequence set forth in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence set forth in SEQ ID NO:8, the CDRL2 amino acid sequence set forth in SEQ ID NO:9, and the CDRL3 amino acid sequence set forth in SEQ ID NO:10, and comprises a heavy chain Fc domain (e.g., IgG1 Fc) having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

[0133] The present invention also provides a method of reducing absolute blood eosinophil count in a subject, comprising the steps of: The method further comprising: a) identifying a subject with asthma (e.g., mild, moderate or severe asthma, e.g., mild, moderate or severe eosinophilic asthma); and b) administering to the subject an antigen-binding protein that binds to IL-5 in an amount of about 100 mg to about 300 mg at a frequency of about once every six months. thereby decreasing the absolute blood eosinophil count in said subject, wherein the antigen binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4.

[0134] The present invention also provides a method of reducing absolute blood eosinophil count in a subject, comprising the steps of: The method further comprising: a) identifying a subject with asthma (e.g., mild, moderate or severe asthma, e.g., mild, moderate or severe eosinophilic asthma); and b) administering to the subject an antibody that binds to IL-5 in an amount of about 100 mg to about 300 mg at a frequency of about once every six months. thereby decreasing the absolute blood eosinophil count in said subject, The antigen binding protein comprises a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2.

[0135] One embodiment of the method of the present disclosure comprises: a) performing a first measurement of absolute blood eosinophil count in a subject; b) performing a second measurement of absolute blood eosinophil count in the subject after administering to the subject a therapeutically effective amount of the antigen binding protein; and c) comparing the first measurement and the second measurement to determine the efficacy of the treatment. Further includes:

[0136] One embodiment of the method of the present disclosure comprises: a) performing a first measurement of absolute blood eosinophil count in a subject; b) performing a second measurement of absolute blood eosinophil count in the subject after administering to the subject a therapeutically effective amount of the antigen binding protein; and c) comparing the first measurement and the second measurement. wherein the subject has an absolute blood eosinophil count selected from the group consisting of: greater than or equal to 150 cells per μL, greater than or equal to 200 cells per μL, and greater than or equal to 350 cells per μL.

[0137] In one embodiment, the method comprises administering about 100 mg of the antigen binding protein.

[0138] In one embodiment, the method comprises administering the antigen binding protein subcutaneously.

[0139] In one embodiment, the subject (pre-treatment) has an absolute blood eosinophil count selected from the group consisting of 150 cells / μL or greater (eg, 200 cells / μL or greater).

[0140] In some embodiments, described herein are methods of reducing absolute blood eosinophil counts, the methods comprising administering to a subject an antigen binding protein that binds IL-5, and wherein absolute blood eosinophil counts are maintained or reduced compared to a pre-treatment baseline. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, described herein are methods of treating asthma, the methods comprising administering to a subject an antigen binding protein that binds IL-5, and wherein absolute blood eosinophil counts are maintained or reduced compared to a pre-treatment baseline. In some embodiments, at least about 1, about 2, about 3, about 4, about 5, about 8, about 10, about 12, about 15, about 18, about 20, about 24, about 26, about 30, about 32, about 36, about 40, or about 50 weeks after a single administration of an antigen binding protein that binds IL-5 to a subject, the blood eosinophil count is reduced by ≧50%, ≧55%, ≧60%, ≧65%, ≧70%, ≧75%, ≧80%, ≧85%, ≧90%, ≧95% compared to the baseline before administration. In some embodiments, at least about 26 weeks after a single administration of an antigen binding protein to a subject, the absolute blood eosinophil count is reduced by ≧50%, ≧55%, ≧60%, ≧65%, ≧70%, ≧75%, ≧80% compared to the baseline before administration. In some embodiments, at least about 32 weeks after a single administration of an antigen binding protein to a subject, the absolute blood eosinophil count is reduced by ≧50%, ≧55%, ≧60%, ≧65%, ≧70%, ≧75%, ≧80% compared to the baseline before administration. In some embodiments, at least about 36 weeks after a single administration of an antigen binding protein to a subject, the absolute blood eosinophil count is reduced by ≧50%, ≧55%, ≧60%, ≧65%, ≧70%, ≧75%, ≧80% compared to the baseline before administration. In some embodiments, at least about 40 weeks after a single administration of an antigen binding protein to a subject, the absolute blood eosinophil count is reduced by ≧50%, ≧55%, ≧60%, ≧65%, ≧70%, ≧75%, ≧80% compared to the baseline before administration.In some embodiments, 100 mg of an antigen binding protein that binds IL-5 is administered to a subject, and 24 weeks after a single administration of the antigen binding protein to the subject, the absolute blood eosinophil count is reduced by at least about 80% compared to the baseline before administration. In some embodiments, 100 mg of an antigen binding protein that binds IL-5 is administered to a subject, and 26 weeks after a single administration of the antigen binding protein to the subject, the absolute blood eosinophil count is reduced by at least about 82% compared to the baseline before administration. In some embodiments, 300 mg of an antigen binding protein that binds IL-5 is administered to a subject, and 26 weeks after a single administration of the antigen binding protein to the subject, the absolute blood eosinophil count is reduced by at least about 83% compared to the baseline before administration. In some embodiments, 300 mg of an antigen binding protein that binds IL-5 is administered to a subject, and 24 weeks after a single administration of the antigen binding protein to the subject, the absolute blood eosinophil count is reduced by at least about 80% compared to the baseline before administration. In some embodiments, an antigen binding protein that binds IL-5 comprises a heavy chain variable region having a CDRH1 amino acid sequence set forth in SEQ ID NO:5, a CDRH2 amino acid sequence set forth in SEQ ID NO:6, and a CDRH3 amino acid sequence set forth in SEQ ID NO:7. In some embodiments, an antigen binding protein that binds IL-5 comprises a light chain variable region having a CDRL1 amino acid sequence set forth in SEQ ID NO:8, a CDRL2 amino acid sequence set forth in SEQ ID NO:9, and a CDRL3 amino acid sequence set forth in SEQ ID NO:10. In some embodiments, an antigen binding protein that binds IL-5 comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256. In some embodiments, an antigen binding protein that binds IL-5 comprises the amino terminus of the heavy chain Fc domain attached to the carboxy terminus of the heavy chain variable region. In some embodiments, an antigen binding protein comprises a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2.In some embodiments, asthma includes mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma or subeosinophilic asthma. In some embodiments, asthma includes severe asthma, e.g., severe eosinophilic asthma.

[0141] The dosing regimens described herein are for use in the treatment of IL-5 mediated diseases, particularly asthma, in a human or animal subject. In one embodiment, the subject is a human.

[0142] The asthma may be selected from mild asthma, moderate asthma, severe asthma, eosinophilic asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, poorly controlled eosinophilic asthma, eosinophilic asthma or subeosinophilic asthma. In one embodiment, the asthma is mild or moderate asthma. In one embodiment, the asthma is severe asthma. The present invention finds particular use in subjects with asthma having an eosinophilic phenotype. Thus, in a further embodiment, the asthma is mild, moderate or severe eosinophilic asthma.

[0143] Pharmaceutical Compositions It is common to provide antigen-binding proteins as pharmaceutical compositions. In one embodiment, a pharmaceutical composition comprising an antigen-binding protein of the present invention further comprises a pharma- ceutically acceptable excipient. In a further embodiment, a pharmaceutical composition comprises an antigen-binding protein of the present invention and one or more pharma- ceutically acceptable excipients.

[0144] In one aspect, the present invention provides a pharmaceutical composition comprising about 100 mg to about 300 mg of an antigen-binding protein that binds to IL-5 and a pharma- ceutically acceptable excipient, the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The pharmaceutical composition further comprises a heavy chain Fc domain linked to the amino terminus of the heavy chain variable region.

[0145] In one embodiment, the pharmaceutical composition comprises an antigen binding protein of the invention in an amount of about 100 mg and a pharma- ceutically acceptable excipient.

[0146] In one embodiment, the pharmaceutical composition comprises an antigen binding protein of the invention, wherein the heavy chain variable region of the antigen binding protein further comprises the heavy chain FR4 amino acid sequence shown in SEQ ID NO:19.

[0147] In one embodiment, the pharmaceutical composition comprises an antigen-binding protein of the invention, and the heavy chain Fc domain is an IgG1 Fc domain. The heavy chain Fc domain may be a human IgG1 Fc domain.

[0148] In one embodiment, a pharmaceutical composition comprises an antigen binding protein of the invention, the antigen binding protein comprising a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4.

[0149] The present invention also provides a pharmaceutical composition comprising an antigen binding protein that binds IL-5 in an amount of about 100 mg and a pharma- ceutically acceptable excipient, wherein the antigen binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4.

[0150] In one embodiment, a pharmaceutical composition comprises an antigen binding protein of the invention, wherein the antigen binding protein is an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2.

[0151] The present invention also provides a pharmaceutical composition comprising an antigen binding protein that binds IL-5 in an amount of about 100 mg and a pharma- ceutically acceptable excipient, wherein the antigen binding protein comprises a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2.

[0152] In one embodiment, the pharmaceutical composition is formulated for subcutaneous administration.In particular, the pharmaceutical composition may be formulated for administration to human subjects.The subject (before treatment) may have an absolute blood eosinophil count selected from the group consisting of 150 cells / μL or more (e.g., 200 cells / μL or more).

[0153] In one embodiment, the pharmaceutical composition is for administration to a subject about once every 3 months, about once every 4 months, about once every 5 months, or about once every 6 months. In a further embodiment, the pharmaceutical composition is for administration to a subject about once every 6 months.

[0154] In one embodiment, the pharmaceutical composition is administered at a dosing interval (or treatment cycle) of about once every 13 weeks (Q13W), about once every 17 weeks (Q17W), about once every 22 weeks (Q22W), or about once every 26 weeks (Q26W). In a further embodiment, the pharmaceutical composition is for administration to a subject at a frequency of about once every 26 weeks (Q26W).

[0155] In a further aspect, the invention provides a pharmaceutical composition comprising about 100 mg to about 300 mg of an antigen binding protein that binds IL-5 for use in treating an IL-5 mediated disease, e.g., asthma (e.g., mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, uncontrolled eosinophilic asthma, eosinophilic asthma, subeosinophilic asthma), the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region; The pharmaceutical composition is for administration to a subject about once every six months. In one embodiment, the heavy chain variable region of the antigen binding protein further comprises a heavy chain FR4 amino acid sequence as set forth in SEQ ID NO: 19.

[0156] The present invention also provides a pharmaceutical composition comprising about 100 mg to about 300 mg of an antigen binding protein that binds IL-5 for use in treating asthma (e.g., mild, moderate or severe asthma, e.g., mild, moderate or severe eosinophilic asthma), the antigen binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4; The pharmaceutical composition is provided, wherein the pharmaceutical composition is for administration to a human subject about once every six months.

[0157] The present invention also provides a pharmaceutical composition comprising about 100 mg to about 300 mg of an antibody that binds to IL-5 for use in treating asthma (e.g., mild, moderate or severe asthma, e.g., mild, moderate or severe eosinophilic asthma), the antigen-binding protein comprises a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2; The pharmaceutical composition is provided, wherein the pharmaceutical composition is for administration to a human subject about once every six months.

[0158] 28Y042-7F11-1 or antigen binding proteins of the disclosure can be provided as a lyophilized powder comprising the antibody and excipients, which can be reconstituted with a pharma- ceutically acceptable carrier (e.g., sterile water). This reconstituted pharmaceutical composition can then be administered (e.g., with further dilution) either subcutaneously or intravenously. 28Y042-7F11-1 or antigen binding proteins of the disclosure can also be provided as a liquid formulation comprising the antibody, excipients, and a pharma- ceutically acceptable carrier. This liquid pharmaceutical composition can then be administered (e.g., with further dilution) either subcutaneously or intravenously.

[0159] The pharmaceutical compositions described herein may include a purified preparation of an antigen binding protein described herein. For example, the pharmaceutical preparation may include a purified preparation of an antigen binding protein described herein in combination with a pharma- ceutically acceptable carrier.

[0160] Typically, such pharmaceutical compositions will contain known pharma- ceutically acceptable carriers as required by accepted pharmaceutical practice, such as sterile carriers, e.g., saline, Ringer's solution, or dextrose solution, optionally buffered to a pH of 5-8 with a suitable buffer.

[0161] The pharmaceutical compositions may be administered by injection or infusion (e.g., intravenously, intraperitoneally, intradermally, subcutaneously, intramuscularly or intraportally, especially subcutaneously). Such compositions are preferably free of visible particulate matter.

[0162] The formulations described herein are stable pharmaceutical compositions.

[0163] Preferably, the pharmaceutical composition comprises an aqueous liquid formulation. The pharmaceutical composition may have a pH of 5 to 8. For example, the pharmaceutical composition may have a pH of 5.5 to 7.5, such as a pH of 5.8 to 7.2, 5.9 to 6.7, or 6.0 to 6.5. In particular, the pharmaceutical composition has a pH of about 6.0. In some embodiments, the pharmaceutical composition has a pH of about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, or about 6.6.

[0164] Methods for preparing such pharmaceutical compositions are well known to those skilled in the art. The pharmaceutical composition may contain the antigen-binding protein in unit dosage form, optionally with instructions for use. The pharmaceutical composition may be lyophilized (freeze-dried) for reconstitution prior to administration, according to methods well known or apparent to those skilled in the art. If the antibody has an IgG1 isotype, a citrate (e.g., sodium citrate) or a copper chelator, such as EDTA or histidine, may be added to the pharmaceutical composition to reduce the extent of copper-mediated degradation of antibodies of this isotype. The pharmaceutical composition may also contain a solubilizer, such as arginine, a surfactant / anti-aggregating agent, such as polysorbate 80, and an inert gas, such as nitrogen, to replace oxygen in the headspace of the vial.

[0165] The composition of the present disclosure may further comprise a buffer selected from the group consisting of histidine, sodium phosphate dibasic heptahydrate, phosphate, citric acid, citrate, sodium phosphate, potassium phosphate and sodium citrate, the buffer providing a pH of 5.8 to 7.2 or a pH of 6.0 to 6.6, the pH value being preferably 6.0. The buffer in the composition of the present disclosure may be present at about 10 to about 30 mM, about 10 to about 20 mM, about 20 mM or about 15.5 mM. In one embodiment, the composition comprises about 5 to about 50 mM, for example, about 10 to about 50 mM, about 10 to about 30 mM or about 10 to about 20 mM histidine. For example, the buffer in the composition of the present disclosure is present at about 20 mM histidine.

[0166] In some embodiments, the composition comprises a surfactant. A "surfactant" is a surface active agent that can exert its effect at the surfaces of solid-solid, solid-liquid, liquid-liquid and liquid-gas interfaces due to its chemical composition that contains both hydrophilic and hydrophobic groups. Surfactants can reduce the concentration of proteins in dilute solutions at gas-water and / or water-solid interfaces where proteins may adsorb and aggregate. Surfactants can bind to hydrophobic interfaces in protein formulations. Some parenterally acceptable non-ionic surfactants contain either polysorbate or polyether groups. Polysorbate 20 and 80, especially polysorbate 80 (PS80), are suitable surfactant stabilizers in the compositions of the present disclosure. Thus, the compositions of the present disclosure may further comprise polysorbate 80. Polysorbate 80 may be present at about 0.01 to about 0.1% weight / volume, such as about 0.01% to about 0.05% or about 0.01 to about 0.03% w / v. For example, Polysorbate 80 may be present in the compositions of the present disclosure at about 0.02% weight / volume (0.02% w / v).

[0167] The composition of the present disclosure may further contain EDTA, which may contribute to the stability of the formulation. EDTA may be present at about 0.01 to about 0.1 mM, for example, about 0.02 to about 0.08 mM or about 0.03 to about 0.06 mM. For example, EDTA may be present at about 0.05 mM. The composition of the present disclosure may contain 20 to 60 mM histidine. The composition of the present disclosure may contain 30 to 110 mM arginine. The composition of the present disclosure may contain 0 to 30 mM methionine. The composition of the present disclosure may contain 0 to 110 mM glycine. The composition of the present disclosure may contain 0 to 350 mM trehalose.

[0168] The composition of the present disclosure may further comprise a sugar. In some embodiments, the composition comprises a polyol. In some embodiments, the polyol is a sugar, preferably a non-reducing sugar. In some embodiments, the non-reducing sugar is trehalose. Thus, the composition of the present disclosure may further comprise trehalose. In some embodiments, the composition comprises about 100 mM to about 250 mM, for example, about 150 mM to about 200 mM, particularly about 160 mM to about 190 mM, of trehalose. For example, trehalose may be present at about 180 mM.

[0169] The composition may also include a solubilizing agent, such as arginine, e.g., L-arginine-HCl. In some embodiments, the composition includes about 10 mM to about 120 mM, e.g., about 20 mM to about 100 mM, particularly about 30 mM to about 50 mM, arginine. In some embodiments, the composition includes about 40 mM arginine.

[0170] In one embodiment, the pharmaceutical composition comprises one or more pharma- ceutically acceptable excipients selected from histidine, trehalose, arginine, EDTA, and polysorbate 80. In a further embodiment, the pharmaceutical composition comprises histidine, trehalose, arginine, EDTA, and polysorbate 80. In some embodiments, the pharmaceutical composition comprises glycine.

[0171] In one embodiment, the pharmaceutical composition comprises about 20 mM histidine, about 180 mM trehalose, about 40 mM arginine, about 0.05 mM EDTA, and about 0.02% weight / volume polysorbate 80.

[0172] As expected, any excipients utilized will be pharma- ceutically acceptable and compatible with the other components of the composition (other excipients and active ingredients).In accordance with another aspect of the present invention, there is also provided a process for preparing a pharmaceutical composition, comprising mixing an antigen-binding protein of the present invention in an amount of about 100 mg to about 300 mg (preferably 100 mg) with a pharma- ceutically acceptable excipient.

[0173] The pharmaceutical compositions for use in treating IL-5 mediated diseases according to the present invention may be administered subcutaneously. Such compositions may be prepared by any method known in the pharmaceutical art, for example by combining the active ingredient with the excipients.

[0174] In one embodiment, the invention provides an antigen binding protein disclosed herein for use in treating an IL-5 mediated disease, e.g., asthma, in a human or animal subject, by subcutaneous administration in an amount of about 100 mg to about 300 mg at a frequency of about once every six months.

[0175] In a further aspect, the invention provides an antigen binding protein as disclosed herein for use in treating an IL-5 mediated disease, e.g., asthma, by subcutaneous administration in a human or animal subject, about once every six months, in an amount of about 30 mg to about 300 mg, or about 30 to about 200 mg, for example, the dosage can be about 30 mg to about 100 mg, e.g., 40 mg or more, 50 mg or more, 60 mg or more, 70 mg or more, 80 mg or more, or 90 mg or more, administered once every six months.

[0176] The pharmaceutical composition may be provided in a unit dosage form, which contains a predetermined amount of active ingredient per unit dosage. A preferred unit dosage form composition contains a full daily dose or sub-dose or a suitable fraction thereof of active ingredient. Thus, a unit dosage containing a sub-dose of a recommended daily dose may be administered multiple times to adjust to a total daily dose. For example, if the dose on a particular day is 100 mg, it may be contained in one unit, or it may be contained in multiple units (e.g., 2 units each containing 50 mg of active ingredient). In one embodiment, the pharmaceutical composition is in a unit dosage form.

[0177] Pre-filled syringe The present invention provides a pre-filled syringe containing about 100 mg to about 300 mg of the antigen-binding protein of the present invention. In one embodiment, a pre-filled syringe containing the pharmaceutical composition disclosed herein is provided.

[0178] In one aspect, the present invention provides a method for producing a) about 100 mg to about 300 mg (e.g., about 100 mg) of an antigen-binding protein that binds to IL-5, and b) Pharmaceutically acceptable excipients A prefilled syringe comprising: the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The pre-filled syringe is provided, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

[0179] In a further aspect, the present invention provides a pre-filled syringe comprising about 30 mg to about 300 mg or about 30 mg to about 200 mg of the antigen-binding protein of the present invention; for example, the pre-filled syringe may contain about 30 mg to about 100 mg, for example, 40 mg or more, 50 mg or more, 60 mg or more, 70 mg or more, 80 mg or more, 90 mg or more of the antigen-binding protein.

[0180] In one embodiment, a pre-filled syringe comprising the pharmaceutical composition disclosed herein is provided.

[0181] In one embodiment, the heavy chain variable region of the antigen binding protein further comprises the heavy chain FR4 amino acid sequence set forth in SEQ ID NO: 19. In another embodiment, the heavy chain Fc domain is an IgG1 Fc domain. In a further embodiment, the heavy chain Fc domain is a human IgG1 Fc domain.

[0182] In one embodiment, the antigen binding protein comprises a heavy chain variable region sequence having the amino acid sequence shown in SEQ ID NO: 3 and a light chain variable region sequence having the amino acid sequence shown in SEQ ID NO: 4. Thus, the present invention also provides a pre-filled syringe comprising about 100 mg of an antigen binding protein that binds to IL-5 and a pharma- ceutically acceptable excipient, wherein the antigen binding protein comprises a heavy chain having a heavy chain variable region sequence having the amino acid sequence shown in SEQ ID NO: 3 and a light chain variable region sequence having the amino acid sequence shown in SEQ ID NO: 4.

[0183] In one embodiment, the antigen-binding protein is an antibody comprising a heavy chain having the amino acid sequence shown in SEQ ID NO: 1 and a light chain having the amino acid sequence shown in SEQ ID NO: 2. Thus, the present invention also provides a pre-filled syringe comprising about 100 mg of an antibody that binds to IL-5 and a pharma- ceutically acceptable excipient, wherein the antibody comprises a heavy chain having the amino acid sequence shown in SEQ ID NO: 1 and a light chain having the amino acid sequence shown in SEQ ID NO: 2.

[0184] In one embodiment, the pre-filled syringe is for subcutaneous administration.In a further embodiment, the pre-filled syringe is administered to a human subject.The subject (before treatment) may have an absolute blood eosinophil count selected from the group consisting of 150 cells / μL or more (e.g., 200 cells / μL or more).

[0185] In one embodiment, the pre-filled syringe is administered at a frequency of about once every 6 months. In one embodiment, the pre-filled syringe is administered at a frequency of about once every 26 weeks (Q26W).

[0186] In one embodiment, the pre-filled syringe contains an aqueous liquid formulation. The formulation may contain a solubilizer as described herein, such as arginine, a surfactant / anti-aggregating agent, such as polysorbate 80, a polyol, such as a sugar, and / or a buffering agent.

[0187] The prefilled syringe may contain a buffer selected from the group consisting of histidine, sodium phosphate dibasic heptahydrate, phosphate, citric acid, citrate, sodium phosphate, potassium phosphate and sodium citrate, the buffer providing a pH of pH 5.8 to pH 7.2 or a pH of pH 6.0 to pH 6.6, preferably a pH value of 6.0. The buffer may be present at about 10 to about 30 mM, about 10 to about 20 mM, about 20 mM or about 15.5 mM. In one embodiment, the formulation present in the prefilled syringe contains about 5 to about 50 mM, for example, about 10 to about 50 mM, about 10 to about 30 mM or about 10 to about 20 mM histidine. For example, the buffer is present at about 20 mM histidine.

[0188] In some embodiments, the prefilled syringe comprises a surfactant. Polysorbate 20 and 80, particularly polysorbate 80 (PS80), are suitable surfactant stabilizers in the compositions of the present invention. Thus, the formulation present in the prefilled syringe may further comprise polysorbate 80. Polysorbate 80 may be present at about 0.01 to 0.1% weight / volume, for example, about 0.01% to about 0.05% or about 0.01 to about 0.03% w / v. For example, polysorbate 80 may be present in the formulation at about 0.02% weight / volume (0.02% w / v).

[0189] The pre-filled syringe may further contain EDTA. EDTA may be present at about 0.01 to 0.1 mM, for example, about 0.02 to about 0.08 mM or about 0.03 to about 0.06 mM. For example, EDTA may be present at about 0.05 mM.

[0190] The prefilled syringe may further comprise a sugar. In some embodiments, the formulation present in the prefilled syringe comprises a polyol. In some embodiments, the polyol is a sugar, preferably a non-reducing sugar. In some embodiments, the non-reducing sugar is trehalose. The composition present in the prefilled syringe may further comprise trehalose. In some embodiments, the formulation present in the prefilled syringe comprises about 100 mM to about 250 mM trehalose, for example, about 150 mM to about 200 mM, particularly about 160 mM to about 190 mM trehalose. For example, trehalose may be present at about 180 mM.

[0191] The pre-filled syringe may also contain a solubilizer, such as arginine, for example, L-arginine-HCl. In some embodiments, the formulation present in the pre-filled syringe contains about 10 mM to about 120 mM, for example, about 20 mM to about 100 mM, particularly about 30 mM to about 50 mM arginine. In some embodiments, the composition contains about 40 mM arginine.

[0192] In particular, the aqueous liquid formulation has a pH of about 6.0. In particular, the aqueous liquid formulation has a pH of about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5 or about 6.6. The formulation preferably comprises an antigen binding protein and one or more pharma- ceutically acceptable excipients. The excipients may be selected from one or more of histidine, trehalose, arginine, EDTA and polysorbate 80. In a further embodiment, the excipients comprise histidine, trehalose, arginine, EDTA and polysorbate 80. In a further embodiment, the pre-filled syringe contains an aqueous liquid formulation comprising an antigen binding protein and about 20 mM histidine, about 180 mM trehalose, about 40 mM arginine, about 0.05 mM EDTA, and about 0.02% weight / volume polysorbate 80, at a pH of about 6.0.

[0193] In some embodiments, the prefilled syringe may contain EDTA present at about 0.01 to about 0.1 mM, for example, about 0.02 to about 0.08 mM or about 0.03 to about 0.06 mM. For example, EDTA may be present at about 0.05 mM. In some embodiments, the prefilled syringe may contain 20 to 60 mM histidine. In some embodiments, the prefilled syringe may contain 30 to 110 mM arginine. In some embodiments, the prefilled syringe may contain 0 to 30 mM methionine. In some embodiments, the prefilled syringe may contain 0 to 110 mM glycine. In some embodiments, the prefilled syringe may contain 0 to 350 mM trehalose.

[0194] In one aspect, the present invention provides a pre-filled syringe as disclosed herein for use in treating IL-5 mediated disease.The IL-5 mediated disease can be asthma.In particular, the asthma is selected from the group consisting of mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, poorly controlled eosinophilic asthma, eosinophilic asthma and subeosinophilic asthma.The asthma can be mild or moderate asthma, for example mild or moderate eosinophilic asthma.The asthma can be severe asthma, for example severe eosinophilic asthma.

[0195] In one embodiment, the pre-filled syringe is provided in a safety syringe device (SSD) or auto-injector, such devices being well known to those skilled in the art.

[0196] Combination Therapy In certain embodiments, antigen binding proteins according to the invention may be administered in combination with one or more (e.g., two) other therapeutic agents that treat an IL-5 mediated disease, e.g., asthma.

[0197] These additional therapeutic agents may be administered via the same route of administration or a different route of administration. Furthermore, they may be administered in the same dosage / dosage regimen as the antigen binding protein or pharmaceutical composition according to the invention.

[0198] When an additional therapeutic agent is utilized, in one embodiment, the combined effect of the antigen binding protein and the additional therapeutic agent is greater than the sum or each acting separately. Thus, the combination of two or more therapeutic agents may result in a synergistic effect.

[0199] Combination therapy with one or more additional therapeutic agents includes co-administration (simultaneous administration), sequential administration, or consecutive administration. Agents intended for use in combination may be formulated in separate compositions or, where the same dosing regimen can be used for all agents, may be formulated in a single pharmaceutical composition.

[0200] Terms In summary, the present disclosure includes the following: Clause 1. A pharmaceutical composition comprising about 100 mg to about 300 mg of an antigen-binding protein that binds to IL-5 and a pharma- ceutically acceptable excipient, the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The pharmaceutical composition, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region. Clause 2. The pharmaceutical composition of clause 1, comprising about 100 mg or about 200 mg of said antigen binding protein. Clause 3. The pharmaceutical composition of clause 1 or clause 2, wherein the heavy chain variable region of the antigen binding protein further comprises a heavy chain FR4 amino acid sequence as set forth in SEQ ID NO:19. Clause 4. The pharmaceutical composition of any one of clauses 1 to 3, wherein the heavy chain Fc domain is an IgG1 Fc domain. Clause 5. The pharmaceutical composition of any one of clauses 1 to 4, wherein the heavy chain Fc domain is a human IgG1 Fc domain. Clause 6. The pharmaceutical composition of any one of clauses 1 to 5, wherein the antigen-binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4. Clause 7. The pharmaceutical composition according to any one of clauses 1 to 6, wherein the antigen-binding protein is an antibody comprising a heavy chain having the amino acid sequence shown in SEQ ID NO:1 and a light chain having the amino acid sequence shown in SEQ ID NO:2. Clause 8. The pharmaceutical composition according to any one of clauses 1 to 7, wherein the pharmaceutical composition is for subcutaneous administration. Clause 9. The pharmaceutical composition according to any one of clauses 1 to 8, which is administered at a frequency of about once every six months. Clause 10. The pharmaceutical composition of any one of clauses 1 to 8, which is administered at a frequency of about once every 26 weeks (Q26W). Clause 11. The pharmaceutical composition according to any one of clauses 1 to 10, which is administered to a human subject. Clause 12. The pharmaceutical composition of clause 11, wherein the human subject has an absolute blood eosinophil count (BEC) of greater than or equal to 200 cells per μL, or greater than or equal to 300 cells per μL. Clause 13. The pharmaceutical composition of any one of clauses 1-12, comprising an aqueous liquid formulation comprising the antigen binding protein and histidine, trehalose, arginine, EDTA and / or polysorbate 80 at a pH of about 6.0. Clause 14. The pharmaceutical composition of any one of clauses 1-13, comprising the antigen binding protein and an aqueous liquid formulation comprising about 20 mM histidine, about 180 mM trehalose, about 40 mM arginine, about 0.05 mM EDTA, and about 0.02% weight / volume polysorbate 80 at a pH of about 6.0. Clause 15. A pharmaceutical composition according to any one of clauses 1 to 14 for use in the treatment of an IL-5 mediated disease. Clause 16. The pharmaceutical composition according to clause 15, wherein the IL-5 mediated disease is asthma, inflammatory bowel disease (IBD), allergic bronchopulmonary aspergillosis (ABPA), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), nasal polyposis (NP), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis without nasal polyps (CRSsNP) or dermatitis. Clause 17. The pharmaceutical composition according to clause 16, wherein the disease is HES, EGPA, CRSsNP or CRSwNP. Clause 18. The pharmaceutical composition according to clause 16 or clause 17, wherein the EGPA is relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis. Clause 19. An antigen binding protein that binds IL-5 for use in treating an IL-5 mediated disease by administration to a subject at a dose of about 100 mg to about 300 mg about once every six months, the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The antigen-binding protein, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region. Clause 20. The antigen-binding protein for use according to clause 19, wherein said dose is about 100 mg. Clause 21. The antigen binding protein for use according to clause 19 or clause 20, wherein the heavy chain variable region of said antigen binding protein further comprises a heavy chain FR4 amino acid sequence as set forth in SEQ ID NO:19. Clause 22. The antigen binding protein for use according to any one of clauses 19 to 21, wherein said heavy chain Fc domain is an IgG1 Fc domain. Item 23. The antigen-binding protein for use according to any one of clauses 19 to 22, wherein the heavy chain Fc domain is a human IgG1 Fc domain. Clause 24. The antigen binding protein for use according to any one of clauses 19 to 23, wherein said antigen binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4. Clause 25. The antigen-binding protein for use according to any one of clauses 19 to 24, wherein said antigen-binding protein is an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2. Clause 26. The antigen-binding protein for use according to any one of clauses 19 to 25, which is administered subcutaneously to said subject. Clause 27. The antigen binding protein for use according to any one of clauses 19 to 26, which is administered to a human subject, such as an adult human subject or a pediatric human subject. Clause 28. The antigen binding protein for use according to clause 27, wherein the human subject has an absolute blood eosinophil count of greater than or equal to 200 cells per μL, or greater than or equal to 300 cells per μL. Clause 29. The antigen binding protein for use according to any one of clauses 19 to 28, wherein said IL-5 mediated disease is selected from asthma, inflammatory bowel disease (IBD), allergic bronchopulmonary aspergillosis (ABPA), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), nasal polyposis (NP), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis without nasal polyps (CRSsNP) or dermatitis. Clause 30. The antigen-binding protein for use according to Clause 29, wherein the EGPA is relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis. Clause 31. The antigen binding protein for use according to clause 29, wherein (i) the disease is CRSsNP and the human subject has type 2 or eosinophilic endotype with elevated eosinophil levels in the nasal mucosa, for example the human subject has blood eosinophils of > 150 / μL, for example blood eosinophils of > 300 / μL, or (ii) the disease is CRSwNP and the human subject has an endoscopic NP score of at least 5 out of a maximum score of 8 with a minimum score of 2 in each nasal passage. Clause 32. A pharmaceutical composition for use in treating an IL-5 mediated disease, comprising about 100 mg to about 300 mg of an antigen binding protein that binds IL-5, the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region; The pharmaceutical composition, wherein the pharmaceutical composition is for administration to a subject about once every six months. Clause 33. A pharmaceutical composition for use according to clause 32, comprising about 100 mg of said antigen binding protein. Clause 34. The pharmaceutical composition for use according to clause 32 or clause 33, wherein said heavy chain variable region of said antigen binding protein further comprises a heavy chain FR4 amino acid sequence as set forth in SEQ ID NO:19. Clause 35. The pharmaceutical composition for use according to any one of clauses 32 to 34, wherein the heavy chain Fc domain is an IgG1 Fc domain. Clause 36. The pharmaceutical composition for use according to any one of clauses 32 to 35, wherein said heavy chain Fc domain is a human IgG1 Fc domain. Clause 37. The pharmaceutical composition for use according to any one of clauses 32 to 36, wherein said antigen binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4. Clause 38. The pharmaceutical composition for use according to any one of clauses 32 to 37, wherein the antigen-binding protein is an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO:1 and a light chain having the amino acid sequence set forth in SEQ ID NO:2. Clause 39. The pharmaceutical composition for use according to any one of clauses 32 to 38, wherein the pharmaceutical composition is for subcutaneous administration. Clause 40. A pharmaceutical composition for use according to any one of clauses 32 to 39, to be administered to a human subject. Clause 41. The pharmaceutical composition for use according to clause 40, wherein the human subject has an absolute blood eosinophil count of 200 cells / μL or more, or 300 cells / μL or more. Clause 42. The pharmaceutical composition for use according to any one of clauses 32 to 41, wherein said IL-5 mediated disease is selected from asthma, inflammatory bowel disease (IBD), allergic bronchopulmonary aspergillosis (ABPA), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), nasal polyposis (NP), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis without nasal polyps (CRSsNP) or dermatitis. Clause 43. A pharmaceutical composition for use according to any one of clauses 32 to 42, comprising an aqueous liquid formulation comprising said antigen binding protein and histidine, trehalose, arginine, EDTA and / or polysorbate 80 at a pH of about 6.0. Clause 44. A pharmaceutical composition for use according to any one of clauses 32 to 43, comprising the antigen binding protein and an aqueous liquid formulation comprising about 20 mM histidine, about 180 mM trehalose, about 40 mM arginine, about 0.05 mM EDTA and about 0.02% weight / volume polysorbate 80 at a pH of about 6.0. Clause 45. A method for treating an IL-5 mediated disease, comprising: the method comprises administering to a subject in need thereof an antigen-binding protein that binds to IL-5 in an amount of about 100 mg to about 300 mg about once every six months; the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The method, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region. Clause 46. The method of clause 45, wherein said IL-5 mediated disease is selected from asthma, inflammatory bowel disease (IBD), allergic bronchopulmonary aspergillosis (ABPA), eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), nasal polyposis (NP), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic rhinosinusitis without nasal polyps (CRSsNP) or dermatitis. Clause 47. The method of clause 48, wherein said asthma is selected from the group consisting of eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic rhinosinusitis without nasal polyps (CRSsNP). Clause 48. A method of treating an IL-5 mediated disease in a subject, comprising: The method further comprising: a) identifying a subject having a disease selected from the group consisting of eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic rhinosinusitis without nasal polyps (CRSsNP); and b) administering to the subject about 100 mg to about 300 mg of an antigen-binding protein that binds to IL-5 at a frequency of about once every six months. thereby treating said disease in said subject; the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The method, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region. Clause 49. The method of any one of clauses 47-48, wherein said method comprises administering about 100 mg or about 200 mg of said antigen binding protein. Clause 50. The method of clause 49, wherein the IL-5 mediated disease is eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome (HES), and the method comprises administering the antigen binding protein in an amount of about 200 mg. Clause 51. The method of clause 49, wherein said IL-5 mediated disease is selected from chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP), and said method comprises administering said antigen binding protein in an amount of about 100 mg. Clause 52. The method of any one of clauses 47-51, wherein said heavy chain variable region of said antigen binding protein further comprises a heavy chain FR4 amino acid sequence as set forth in SEQ ID NO:19. Clause 53. The method of any one of clauses 47 to 52, wherein the heavy chain Fc domain is an IgG1 Fc domain. Clause 54. The method of any one of clauses 47 to 53, wherein the heavy chain Fc domain is a human IgG1 Fc domain. Clause 55. The method of any one of clauses 47 to 54, wherein the antigen-binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4. Clause 56. The method of any one of clauses 47 to 55, wherein the antigen-binding protein is an antibody comprising a heavy chain having the amino acid sequence shown in SEQ ID NO:1 and a light chain having the amino acid sequence shown in SEQ ID NO:2. Clause 57. The method of any one of clauses 47-56, wherein said antigen binding protein is administered subcutaneously. Clause 58. The method of any one of clauses 47 to 57, wherein the subject is a human subject. Clause 59. The method of any one of clauses 47 to 58, wherein the subject (a) has, at screening at the start of treatment, (i) an absolute blood eosinophil count of 200 or more, or 300 or more, or (ii) an absolute blood eosinophil count of 150 or more, and / or (b) a blood eosinophil count of 300 or more, or more, in the past 12 months, at screening at the start of treatment. Clause 60. A method for reducing absolute blood eosinophil count in a subject, comprising: The method further comprising: a) identifying a subject having a condition selected from the group consisting of eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic rhinosinusitis without nasal polyps (CRSsNP); and b) administering to the subject an antigen-binding protein that binds to IL-5 in an amount of about 100 mg to about 300 mg at a frequency of about once every six months. thereby reducing the absolute blood eosinophil count in the subject, the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The method, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region. Clause 61. The method of clause 63, wherein said method comprises administering about 100 mg or about 200 mg of said antigen binding protein. Clause 62. The method of clause 60 or clause 61, wherein the heavy chain variable region of the antigen binding protein further comprises a heavy chain FR4 amino acid sequence as set forth in SEQ ID NO:19. Clause 63. The method of any one of clauses 60 to 62, wherein the heavy chain Fc domain is an IgG1 Fc domain. Clause 64. The method of any one of clauses 60 to 63, wherein the heavy chain Fc domain is a human IgG1 Fc domain. Clause 65. The method of any one of Clauses 60 to 64, wherein the antigen-binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:4. Clause 66. The method according to any one of clauses 60 to 65, wherein the antigen-binding protein is an antibody comprising a heavy chain having the amino acid sequence shown in SEQ ID NO:1 and a light chain having the amino acid sequence shown in SEQ ID NO:2. Clause 67. The method of any one of clauses 60-66, wherein the antigen binding protein is administered subcutaneously. Clause 68. The method of any one of clauses 60 to 67, wherein the subject is a human subject. Clause 69. The method of any one of clauses 60 to 68, wherein the subject has an absolute blood eosinophil count of greater than or equal to 200 cells per μL or greater than or equal to 300 cells per μL. Clause 70. A pre-filled syringe comprising: a) about 100 mg to about 300 mg (e.g., about 100 mg to about 300 mg in a total volume of about 1 mL) of an antigen-binding protein that binds to IL-5; and b) a pharma- ceutically acceptable excipient, the antigen-binding protein comprises a heavy chain variable region having the CDRH1 amino acid sequence shown in SEQ ID NO:5, the CDRH2 amino acid sequence shown in SEQ ID NO:6, and the CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having the CDRL1 amino acid sequence shown in SEQ ID NO:8, the CDRL2 amino acid sequence shown in SEQ ID NO:9, and the CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The pre-filled syringe, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region. Clause 71. The pre-filled syringe of Clause 70, wherein the pre-filled syringe contains about 100 mg or about 200 mg of the antigen binding protein. Clause 72. The pre-filled syringe of clause 70 or clause 71, wherein the heavy chain variable region of the antigen binding protein further comprises a heavy chain FR4 amino acid sequence as set forth in SEQ ID NO:19. Clause 73. The pre-filled syringe according to any one of clauses 70 to 72, wherein the heavy chain Fc domain is an IgG1 Fc domain. Clause 74. The pre-filled syringe according to any one of clauses 70 to 73, wherein the heavy chain Fc domain is a human IgG1 Fc domain. Clause 75. The prefilled syringe according to any one of clauses 70 to 74, wherein the antigen-binding protein comprises a heavy chain variable region sequence having the amino acid sequence shown in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence shown in SEQ ID NO:4. Clause 76. The prefilled syringe according to any one of clauses 70 to 75, wherein the antigen-binding protein is an antibody comprising a heavy chain having the amino acid sequence shown in SEQ ID NO:1 and a light chain having the amino acid sequence shown in SEQ ID NO:2. Clause 77. The prefilled syringe according to any one of clauses 70 to 76, wherein the prefilled syringe is for subcutaneous administration. Clause 78. The pre-filled syringe of any one of clauses 70 to 77, administered to a subject approximately once every six months. Clause 79. The pre-filled syringe of any one of clauses 70 to 77, administered to a subject at a frequency of about once every 26 weeks (Q26W). Clause 80. A pre-filled syringe according to any one of clauses 70 to 79, for administration to a human subject. Clause 81. A pre-filled syringe according to clause 80, comprising an aqueous liquid formulation comprising the antigen binding protein and histidine, trehalose, arginine, EDTA and / or polysorbate 80, at a pH of about 6.0. Clause 82. A pre-filled syringe according to any one of clauses 70 to 81, comprising the antigen binding protein and an aqueous liquid formulation having a pH of about 6.0 comprising about 20 mM histidine, about 180 mM trehalose, about 40 mM arginine, about 0.05 mM EDTA and about 0.02% weight / volume polysorbate 80. Clause 83. A pre-filled syringe according to any one of clauses 70 to 82 for use in the treatment of an IL-5 mediated disease. Clause 84. The pre-filled syringe according to Clause 88, wherein the IL-5 mediated disease is selected from HES, EGPA, CRSsNP or CRSwNP. Clause 85. A pre-filled syringe according to any one of clauses 74 to 84 provided in a safety syringe device (SSD) or auto-injector. EXAMPLES

[0201] The following examples illustrate various non-limiting aspects of the present invention and are not intended to limit the scope of the invention in any way.

[0202] Interleukin-5 (IL-5) mediates the growth and differentiation of eosinophils in the bone marrow and their recruitment and activation in tissues (Corren, Discov. Med. 2012;13(71):305-312). The circulating half-life of eosinophils is approximately 8-18 hours, although eosinophils can persist longer (days to weeks) in tissues (Kovalszki & Weller, Eosinophilia. 2016;43(4):607-617). Inhibition of IL-5 removes a key eosinophil growth factor. Given the short circulating half-life of eosinophils, inhibition of IL-5 results in a rapid reduction in the circulating population. Depletion of eosinophils using monoclonal antibodies (mAbs) that target IL-5, such as mepolizumab, which is currently approved for the treatment of severe eosinophilic asthma and is in development for other indications, has been identified as a therapeutic strategy for a number of disorders (Legrand & Klion, J. Allergy Clin. Immunol. Pract. 2015;3(2):167-174).

[0203] 28Y042-7F11-1 is a humanized monoclonal antibody (immunoglobulin G1 [IgG1], kappa) with extended pharmacology. It inhibits IL-5 signaling by blocking the binding of human IL-5 to the IL-5 receptor complex expressed on the eosinophil cell surface. Treatment with an anti-IL-5 monoclonal antibody every 4 weeks is well tolerated and has been approved as an add-on maintenance treatment in patients with severe eosinophilic asthma. 28Y042-7F11-1 is expected to provide similar efficacy and benefit:risk profile as other IL-5-targeted monoclonal antibodies when administered at longer dosing intervals.

[0204] Example 1: Dosage Study This example was a single ascending dose first time in human (FTIH) study to investigate the safety, tolerability, immunogenicity, PK and PD of 28Y042-7F11-1 administered subcutaneously in participants with mild to moderate asthma maintained on low to medium daily doses of inhaled corticosteroids (ICS) or ICS / long-acting beta-agonists (LABA) and short-acting beta-agonists (SABA).

[0205] method research design An overview of the first-in-human study design for 28Y042-7F11-1 is shown in Figure 1. Each participant received a single dose of 28Y042-7F11-1 or placebo as shown in Figure 1.

[0206] participants Eligible participants were required to have a blood eosinophil count of ≥ 200 cells / μL at screening to facilitate investigation of blood eosinophil count reductions after single ascending doses of 28Y042-7F11-1 and to quantify the long-term blood eosinophil reduction expected in humans given the expected prolonged half-life and greater IL-5 affinity of 28Y042-7F11-1. A blood eosinophil pre-screening assessment was performed. Participants were eligible to skip the blood eosinophil pre-screening visit and proceed directly to the screening visit if they had a documented blood test result within 12 weeks prior to dosing demonstrating a blood eosinophil level of ≥ 200 cells / μL.

[0207] After successful completion of screening, 48 participants with mild-moderate asthma and blood eosinophils ≥ 200 cells / μL at screening were randomized and dosed. Participants were randomized according to a randomization schedule generated by Biostatistics prior to study initiation using validated internal software. Participants in each dose cohort were assigned in a 3:1 (active:placebo) ratio.

[0208] Follow-up periods were up to 40 weeks after dosing and were dose-dependent based on predicted blood eosinophil profiles: participants in the 2 mg and 10 mg 28Y042-7F11-1 cohorts attended clinics for up to 32 weeks, participants in the 30 mg and 100 mg 28Y042-7F11-1 cohorts attended clinics for up to 36 weeks, and participants in the 300 mg cohort attended clinics for up to 40 weeks.

[0209] treatment As used herein, the term "study treatment" may describe any combination of products that a participant receives according to a protocol design.

[0210] [Table 6]

[0211] Pharmacokinetic evaluation Blood samples for determining plasma concentrations of 28Y042-7F11-1 were collected at pharmacokinetic sampling time points designated as part of the study. Blood samples were obtained via an indwelling cannula (or by direct venipuncture) and collected in tripotassium ethylenediaminetetraacetate (K3EDTA) tubes. Processing of blood samples (i.e., centrifugation followed by collection and storage at -70°C of the resulting plasma) was performed within 2 hours of collection.

[0212] Concentrations of 28Y042-7F11-1 were determined in plasma samples using currently approved bioanalytical methodologies. Raw data were stored at the bioanalytical facility.

[0213] Pharmacodynamic biomarkers Serum samples were collected during the study to measure serum total IL-5 levels as a marker of target engagement. In addition, blood eosinophil levels were measured as part of a hematology panel as a marker of pharmacological response. Samples were collected at time points designated as part of the study.

[0214] result Pharmacokinetic parameters of 28Y042-7F11-1 in plasma Plasma 28Y042-7F11-1 PK parameters obtained after single SC administration of different doses (2 mg to 300 mg) of 28Y042-7F11-1 in participants with mild-to-moderate asthma are summarized in Table 7.

[0215] [Table 7] JPEG2024542777000009.jpg84162

[0216] Across the 2-300 mg SC dose range, AUC(0-∞), AUC(0-t) and Cmax of 28Y042-7F11-1 increased with increasing dose of 28Y042-7F11-1. Median tmax ranged from 8 to 14 days across doses studied. Geometric mean t1 / 2 of 28Y042-7F11-1 ranged from 38 to 53 days across doses and was not dose-dependent (38-44 days was less than twice the t1 / 2 obtained in 4 / 6 participants, except for the 2 mg dose where %AUCex was >20% and t1 / 2 was calculated for that period). There was no evidence of target-mediated deposition. No appreciable changes in CL / F of 28Y042-7F11-1 were observed across the 2 mg to 300 mg SC dose range studied (except for the 2 mg dose), with geometric mean values ​​ranging from 0.0807 to 0.160 L / day (0.118 to 0.160 L / day excluding the 2 mg dose). Similarly, Vz / F of 28Y042-7F11-1 was consistent across the doses studied, with geometric mean values ​​ranging from 6 to 9 L. Extrapolations of the geometric means of AUC(0-∞) were small, ranging from 0.9 to 8% (except for the 2 mg dose [24%]).

[0217] Variability (%CVb) in 28Y042-7F11-1 systemic exposure (Cmax and AUC) was generally low to moderate (7-59%).

[0218] Blood eosinophil count At baseline, geometric mean blood eosinophil counts were similar between placebo (0.359 GI / L) and dose groups (range 0.288 GI / L to 0.398 GI / L), with the lowest baseline geometric mean blood eosinophil count measured for the 2 mg group and the highest baseline geometric mean blood eosinophil count measured for the 30 mg group. Reductions in blood eosinophil counts were evident from the first post-dose assessment (24 hours) in all dose groups (compared to little change in the placebo group), with the greatest reductions observed at week 8 for most dose groups. By week 8, there were no clear differences between dose groups in the magnitude of blood eosinophil count reduction. However, there were dose-related differences in the duration of reduction, with suppression of blood eosinophils maintained longer with increasing dose (Figure 2).

[0219] The results of a Mixed Model Repeated Measures (MMRM) analysis of pairwise baseline ratios for blood eosinophil data adjusted for differences in baseline blood eosinophil counts are shown in FIG.

[0220] At week 26 (6 months), a reduction in blood eosinophils of >80% from baseline was observed in the 100 mg and 300 mg groups, with adjusted geometric mean ratios for baseline blood eosinophils of 0.199 and 0.186, respectively (Table 8). Adjusted geometric mean ratios for these groups for comparison to placebo were 0.178 and 0.166, respectively (i.e., 82% and 83% reductions). The probability of a placebo-adjusted ratio for blood eosinophils to baseline of <0.25 (i.e., a >75% reduction in blood eosinophils) at week 26 was 95% for the 100 mg group and 96% for the 300 mg group (Figure 3 and Table 8).

[0221] [Table 8]

[0222] Because the magnitude of reduction in blood eosinophils was similar for all groups at early time points, it was not appropriate to fit a 4-parameter dose-response Emax Bayesian model at any time point. Analysis of the dose-response relationship was performed with a Bayesian model only at week 26, the most important time point of interest, with measurements in all cohorts. The results of this analysis are shown in Table 9.

[0223] [Table 9]

[0224] Bayesian analysis supported the MMRM analysis, with blood eosinophil reductions of 79% and 83% from baseline observed in the 100 mg and 300 mg groups, respectively (Table 9). The adjusted geometric mean ratios for these groups for comparison to placebo were 0.206 and 0.167, respectively (i.e., 79% and 83% reductions). The probability of a placebo-adjusted ratio to baseline in blood eosinophil counts of less than 0.25 at week 26 (i.e., a >75% reduction in blood eosinophil count) was 87% for the 100 mg group and 96% for the 300 mg group (Table 9).

[0225] A second sensitivity analysis was performed after application of time-windowing to ensure that assessments were obtained within the acceptable time window of scheduled visit dates and times. At week 26, one participant in all treatment groups was excluded due to time deviations. Nevertheless, results were similar to the primary analysis, with a 90% probability for the 100 mg group and a 97% probability for the 300 mg group of having a placebo-adjusted ratio to baseline in blood eosinophil counts of less than 0.25 (i.e., a >75% reduction in blood eosinophil counts) at week 26.

[0226] Serum total IL-5 Geometric mean serum total IL-5 (i.e., free IL-5 plus 28Y042-7F11-1 bound IL-5) values ​​at baseline were (9.206 ng / L) for the placebo group, slightly lower than those of the dose groups (10.376–15.109 ng / L). In general, the majority of participants had baseline values ​​below the limit of quantification of the assay in their respective dose groups. From week 1 (day 8) onwards, all participants in the dose groups had measurable concentrations of serum total IL-5. An increase in serum total IL-5 from baseline was noted for all dose groups at all study visits. However, no clear dose response was observed. Meanwhile, the geometric mean serum total IL-5 values ​​for the placebo group remained similar to baseline throughout the study period (Figure 4).

[0227] Exploratory biomarker results Evaluation of exploratory asthma biomarkers was performed in this study. Levels of eosinophil-derived neurotoxin (EDN), eotaxin, macrophage-derived chemokine (MDC), monocyte chemoattractant protein 4 (MCP-4 / CCL13), and thymus and activation-regulated chemokine (TARC / CCL17) were measured on days -1, 29, and 127. A decrease in the levels of eosinophil-derived neurotoxin was seen with 28Y042-7F11-1 treatment, while no changes were observed in the other markers. These results mirror the findings with mepolizumab treatment using the same biomarker panel.

[0228] safety results This study evaluated the safety and tolerability of single subcutaneous doses of 2 mg, 10 mg, 30 mg, 100 mg, and 300 mg of 28Y042-7F11-1 in participants with mild-to-moderate asthma compared with placebo in adults. All 28Y042-7F11-1 doses were well tolerated by participants. The incidence of treatment-emergent adverse events was 92% for placebo and 81% for all doses. No serious adverse events or adverse events leading to withdrawal from the study were reported.

[0229] conclusion Over the dose range studied, 28Y042-7F11-1 was absorbed slowly with a median observed tmax of 8-14 days and distributed to an apparent volume of distribution of 6-9 L. This volume corresponds approximately to the plasma and interstitial space and is consistent with values ​​reported for typical monoclonal antibodies targeting soluble ligands. After tmax, plasma concentrations of 28Y042-7F11-1 declined in a monoexponential manner with a geometric mean t1 / 2 of 38-53 days and an apparent clearance of 0.0807-0.160 L / day. When compared to mepolizumab (Nucala P1), another anti-IL-5 monoclonal antibody, these values ​​represent an approximately two-fold increase in half-life and an approximately two-fold decrease in apparent clearance. The geometric mean pharmacokinetic parameters (Vz / F, CL / F and t1 / 2) were consistent throughout the dose range studied and therefore dose independent without evidence of target-mediated deposition, implying that the PK of 28Y042-7F11-1 was linear. Furthermore, there was no significant deviation from dose proportionality for Cmax and AUC(0-∞) over the SC dose range of 10 to 300 mg, except for the 2 mg dose.

[0230] Due to the wide range of 28Y042-7F11-1 single SC doses (2-300 mg) investigated in this study over an extended period (up to 40 weeks post-dose), it was possible to assess the dose response of blood eosinophil counts. Significant blood eosinophil count reductions were observed from the first post-dose assessment on day 2 (24 hours), with the greatest reductions observed at week 8 for most dose groups. Reductions were dose-independent up to week 8, but a clear dose response was evident for the return toward baseline. At week 26 (6 months), blood eosinophil reductions compared to placebo after adjusting for baseline blood eosinophil counts were 82% and 83% in the 100 mg and 300 mg groups, respectively. These reductions were similar to those reported with mepolizumab at the approved therapeutic dose (Product Information [PI]). The probability of a placebo-adjusted ratio to baseline in blood eosinophil counts of <0.25 (i.e., a >75% reduction in blood eosinophil counts) at week 26 was 95% for the 100 mg group and 96% for the 300 mg group (MMRM analysis). These probabilities exceeded the predefined success criteria of 80%. These results reflect the increased affinity of 28Y042-7F11-1 for IL-5 as well as an increase in the half-life of the antibody.

[0231] in conclusion: · 28Y042-7F11-1 was well tolerated in adult participants with mild / moderate asthma receiving single doses of up to 300 mg SC of 28Y042-7F11-1. The geometric mean terminal half-life (38-53 days) is increased by approximately 2-fold compared to conventional IgG1 monoclonal antibodies targeting soluble ligands. 28Y042-7F11-1 reduced blood eosinophil counts and a clear dose response was observed for the return toward baseline. At week 26, the adjusted reduction compared to placebo was 82% and 83% in the 100 mg and 300 mg groups, respectively. Both doses met the predefined success criteria for placebo-adjusted ratios to baseline blood eosinophil counts at week 26.

[0232] Using the results from this study and model-informed drug development (MIDD) principles, the dose and dosing frequency of 28Y042-7F11-1 that best fits the established Phase 3 mepolizumab-like blood eosinophil pharmacology is 100 mg once every 6 months (or once every 26 weeks (Q26W) (the terms once every 6 months and Q26W are used interchangeably) with additional flexibility in which patients should delay their next dose (e.g., allowing 4-week flexibility).

[0233] Example 2: Phase III Clinical Protocol - Asthma This prospective example describes the intended Phase III clinical studies. Each placebo-controlled exacerbation study will last 12 months to investigate the effect of two repeated doses of 100 mg SC of 28Y042-7F11-1 on inhaled corticosteroids (ICS) plus additional controller therapy in adult and adolescent (>12 years) patients with eosinophilic phenotype asthma and a history of repeated exacerbations (>2 in the past 12 months), a population that has been shown to benefit clinically from anti-IL-5 treatment. The 12-month study will allow for two repeated doses of 28Y042-7F11-1, which is long enough to assess the efficacy of 28Y042-7F11-1 100 mg SC every 26 weeks on the frequency of clinically significant exacerbations and other relevant outcomes, as well as the safety profile with adequate exposure.

[0234] After a minimum of 1 week (maximum 6 weeks) run-in period, 375 eligible subjects will be randomized 2:1 to receive 28Y042-7F11-1 100 mg SC (n=350) or matching placebo (n=175). The first injection will be administered at randomization. Subjects will have a visit at week 2, a visit at week 4, and then visits at 4-week intervals thereafter, with an additional visit at week 26 to administer the second injection. The final visit (end of study visit) will occur at week 52. Subjects will have the option to continue in a 12-month open-label extension study, in which subjects who have already received 28Y042-7F11-1 will receive up to two additional doses, and subjects who previously received placebo will receive up to two doses of 28Y042-7F11-1.

[0235] Eligible subjects are adult and adolescent males and females (>12 years) with a confirmed diagnosis of asthma receiving medium-to-high dose ICS and at least one other controller. Subjects must have poorly controlled asthma as indicated by >2 exacerbations in the past 12 months despite existing treatment. Subjects must have a blood eosinophil level of >150 cells / μL at screening or >300 cells / μL in the 12 months prior to screening.

[0236] The primary outcome measure is the frequency of clinically significant exacerbations (i.e., exacerbations requiring systemic corticosteroids and / or ER visits and / or hospitalizations) over the 12-month treatment period. In addition to exacerbations, other efficacy measures include lung function (pre- and post-bronchodilator FEV1), asthma control (Asthma Control Questionnaire-ACQ-5), quality of life measured using the St Georges Respiratory Questionnaire (SGRQ), and diary card parameters including peak flow rate attributable to asthma, rescue use, daily symptoms, and nighttime awakenings. Other measures of asthma control and response to treatment will also be evaluated throughout the study.

[0237] Blood eosinophils will be measured throughout the treatment period and small PK samples will be collected (pre-dose, Weeks 2, 12, 26, 28, 40 and 52). The study will include comprehensive safety and immunogenicity assessments to robustly characterize safety outcomes after multiple dosing. Immunogenicity will be assessed pre-dose at Weeks 0, 2, 4, 8, 12, 26, 28, 30, 32, 36, 40 and 52.

[0238] 28Y042-7F11-1 is expected to show a similar clinical profile to mepolizumab. This is supported by the results of the study described in Example 1, which collected pharmacokinetic, pharmacodynamic, safety and tolerability data. Single doses up to 300 mg SC (3x the planned therapeutic dose) were evaluated in subjects with mild-moderate asthma but elevated blood eosinophils (>200 cells / μL at screening). 28Y042-7F11-1 was well tolerated and no safety signals were detected. The effect on blood eosinophils was as predicted from accumulated pharmacological knowledge of mepolizumab, with overall maximum blood eosinophil suppression similar to that seen with mepolizumab 100 mg SC / 75 mg IV, although the duration of suppression was longer compared to that previously seen with mepolizumab.

[0239] Therefore, in addition to the two exacerbation studies, a 12-month supportive study is also proposed to enroll approximately 1,700 adult and adolescent subjects (>= 12 years old) currently receiving either mepolizumab or benralizumab. Subjects will be randomized 1:1 to either continue their existing treatment or be switched to 28Y042-7F11-1 100 mg SC every 26 weeks. Utilizing a non-inferiority design, the study aims to show that treatment with 28Y042-7F11-1 100 mg SC every 26 weeks is non-inferior to existing anti-IL-5 therapy with respect to clinically significant exacerbation rates (i.e., exacerbations requiring systemic corticosteroids and / or ER visits and / or hospitalizations) and other markers of asthma control.

[0240] After a minimum run-in period of 1 week (maximum 6 weeks), 1,600 subjects will be randomized 1:1 to receive 28Y042-7F11-1 100 mg SC once every 26 weeks (n=800) or continue existing treatment (n=800). At randomization, subjects will receive 2 injections of either active 28Y042-7F11-1 100 mg and placebo-matched mepolizumab / benralizumab (according to the subject's prior treatment) or placebo 28Y042-7F11-1 and active mepolizumab 100 mg SC / benralizumab 30 mg SC (according to the subject's prior treatment). Thereafter, clinic visits will occur every 4 weeks, with subjects previously receiving mepolizumab receiving injections of mepolizumab 100 mg SC or matching placebo every 4 weeks. Subjects previously receiving benralizumab will receive injections of benralizumab 30 mg SC or matching placebo every 8 weeks. There will be an additional visit at week 26 for administration of 28Y042-7F11-1 100 mg SC or matching placebo. An end-of-treatment visit will occur at week 52, and a follow-up visit will occur at week 56.

[0241] Eligible subjects are adult and adolescent males and females (>12 years old) who are currently receiving mepolizumab or benralizumab for severe asthma for at least 12 months prior to enrollment and have demonstrated a response to anti-IL-5 therapy as assessed by (1) a ≥50% reduction in exacerbation frequency, (2) a ≥50% reduction in maintenance OCS use, or (3) no exacerbations in the past 6 months while receiving anti-IL-5 therapy and an ACQ-5 score of ≤1.5 at screening. Subjects must have demonstrated clinical benefit from their current anti-IL-5 therapy in either a reduction in exacerbation frequency and / or a reduction in maintenance oral corticosteroid therapy, as confirmed by the treating physician, prior to initiating anti-IL-5 therapy. Subjects must be receiving medium or high doses of inhaled corticosteroids plus another controller medication for the treatment of asthma, as well as receiving anti-IL-5 therapy.

[0242] The primary outcome variable is the frequency of clinically significant exacerbations over the 12-month treatment period. In addition, other efficacy endpoints are lung function (pre- and post-bronchodilator FEV1), asthma control as assessed by the Asthma Control Questionnaire (ACQ-5), quality of life using the St. George's Respiratory Questionnaire (SGRQ), and diary card parameters (symptoms attributable to asthma, peak flow, rescue use, and nocturnal awakenings). Other endpoints of asthma control and response to treatment will also be evaluated throughout the study.

[0243] Blood eosinophils will be measured throughout the treatment period. The study will include comprehensive safety and immunogenicity assessments to robustly characterize safety outcomes after multiple dosing. Immunogenicity will be assessed pre-dose at weeks 0, 4, 8, 12, 26, 40, and 52.

[0244] formulation Previous studies have utilized a 150 mg / mL liquid formulation of 28Y042-7F11-1 injection, supplied in vials as a sterile, preservative-free, single-use aqueous solution. The required dose levels were prepared at the clinical site by dilution with saline and then injected as subcutaneous (SC) doses (single injection for doses up to 100 mg, 3 injections for doses of 300 mg).

[0245] A Phase 3 study will be initiated using a new formulation based on the previous formulation. Changes between the previous and new formulations are that the concentration of 28Y042-7F11-1 has been reduced from 150 mg / mL to 100 mg / mL, methionine has been removed, and the concentrations of some excipients have been reduced (Table 10).

[0246] [Table 10]

[0247] During these studies, 28Y042-7F11-1 injection (100 mg / mL) will be provided as a single-use sterile liquid drug product (DP) in a clear glass prefilled syringe (PFS) that delivers 100 mg of 28Y042-7F11-1 for subcutaneous administration. The primary container and closure of the DP consists of a 1 mL long type I glass siliconized barrel with a thermoplastic elastomer needle shield covered by a hard plastic shield, a 29G thin-walled x 12.7 mm stainless steel needle, and sealed with a bromobutyl elastomer rubber plugger stopper. The prefilled syringe will be assembled into a safety syringe device, i.e., the BD UltraSafe Passive Plus safety device.

[0248] The 28Y042-7F11-1 formulation detailed in Table 10 was found to have particularly good stability, with the drug product remaining stable after storage for up to 18 months at the recommended long-term storage temperature of 2-8°C. In addition, the drug product remained stable after storage for 1 month at -20°C, 0.5 months at 30°C / 65% relative humidity (RH), and after exposure to three freeze-thaw cycles. A shelf life of 30 months applies to the injectable drug product (100 mg / mL) when stored at 2°C-8°C (36°F-46°F) and protected from light.

[0249] Example 3: Modeling to determine dosing for chronic rhinosinusitis with nasal polyps (CRSwNP) and chronic rhinosinusitis without nasal polyps (CRSsNP) The proposed dose and frequency of administration of 28Y042-7F11-1, 100 mg every 26 weeks, for the phase 3 study of CRSwNP was identified using model-informed drug development (MIDD) principles. The dosing regimen of 28Y042-7F11-1 was selected to closely match the blood eosinophil pharmacology observed with mepolizumab in the pivotal phase 3 study in the CRSwNP population throughout the treatment period. Further dose ranges of 28Y042-7F11-1 are not believed to be necessary prior to initiating the proposed phase 3 program in CRSwNP. Simulation analysis indicates that the additional benefit is limited in terms of blood eosinophil reduction above the proposed 100 mg SC dose of 28Y042-7F11-1 administered every 26 weeks; whereas, doses less than that are likely not effective because the dose does not match the desired blood eosinophil pharmacology. A similar approach was applied for dose selection of CRSsNP, assuming equivalent desired blood eosinophil pharmacology between CRSwNP and CRSsNP.

[0250] Desired blood eosinophil pharmacology was reported by a pivotal phase 3 study with mepolizumab. In a pivotal phase 3 study of mepolizumab in CRSwNP, steady-state eosinophil reduction compared to baseline was 84% ​​after mepolizumab 100 mg SC every 4 weeks. This reduction was converted to geometric mean (std logs) blood eosinophil count at 52 weeks, corresponding to 0.06 (0.768) GI / L in the cohort receiving mepolizumab 100 mg SC every 4 weeks. This pharmacology level was associated with clinical efficacy. At the end of the 52-week treatment period, a higher proportion of participants in the mepolizumab group had an improvement of ≥1 point in total endoscopic NP score than those in the placebo group (50% vs. 28%, respectively), and fewer participants in the mepolizumab group had a worsening of total endoscopic NP score over the same period than those in the placebo group (22% vs. 30%, respectively). For the co-primary endpoint of change from baseline in total endoscopic NP score at week 52, the median change was -1.0 in the mepolizumab group compared to 0 in the placebo group. This endpoint showed a statistically significant improvement in favor of mepolizumab. Furthermore, in severe eosinophilic asthma (a disease with which CRSwNP shares many features), the approved mepolizumab dose of 100 mg SC every 4 weeks reduced blood eosinophils by 86% and 81% in phase 3 trials, with a consistent reduction in annualized exacerbation rate ratio of approximately 50%. Simulation analysis indicates that the additional benefit is limited in terms of blood eosinophil reduction above the proposed 28Y042-7F11-1 dosing regimen of 100 mg SC every 26 weeks. Furthermore, simulation analysis indicates that lower doses are likely not effective because they do not match the desired blood eosinophil pharmacology.

[0251] The dose and dosing frequency selection of 28Y042-7F11-1 targets the previous pharmacology of mepolizumab and is effective and rapid for the following reasons: 28Y042-7F11-1 targets the same IL-5 epitope as mepolizumab and is therefore expected to provide similar clinical efficacy in the CRSwNP patient population selected for these studies, as well as in the CRSsNP patient population, by establishing the same blood eosinophil reduction as mepolizumab through the same IL-5 neutralization. · The safety profile of IL-5 neutralization so far has been comparable to placebo.

[0252] The PK-blood eosinophil model used to support dose selection of 28Y042-7F11-1 is an updated model based on the indirect exposure-eosinophil model developed based on data from 16 mepolizumab studies that collected pharmacokinetic samples, blood eosinophil count measurements, and covariates in various eosinophil states and healthy subjects during mepolizumab clinical development. The model was parameterized for baseline blood eosinophils (KRO), clearance rate (KOUT), maximum inhibitory effect (Imax), concentration producing 50% of maximum inhibitory drug effect (IC50), and Hill coefficient (GAMA). Inter-subject variability was incorporated for baseline blood eosinophils and maximum drug effect using an exponential model. Measured baseline blood eosinophil count was a covariate for KRO and Imax. Disease was a covariate for KRO. The model was updated to reflect the longer half-life and enhanced potency of 28Y042-7F11-1 compared to mepolizumab while maintaining the same model structure. Model IC50 parameters, intersubject variability, and unexplained residual variability were estimated based on PK and eosinophil data from a single ascending dose Phase 1 study with 28Y042-7F11-1 in mild-to-severe asthma. The effect of baseline eosinophil levels on maximum achievable drug inhibitory response and on model-predicted baseline blood eosinophils was assumed to be the same between mepolizumab and 28Y042-7F11-1.

[0253] The PK-blood eosinophils simulation of 28Y042-7F11-1 was based on the PK model of 28Y042-7F11-1 developed based on data from a phase 1 study of 28Y042-7F11-1 and an updated PK-blood eosinophils model. The simulated eosinophils level at baseline in CRSwNP reflected the actual value (0.39 GI / L) in the pivotal phase 3 mepolizumab study. The simulated eosinophils level at baseline in CRSsNP reflected the range of values ​​reported for CRSsNP in the literature (0.2-0.4 GI / L; J Allergy Clin. Immunol. 2020 Aug;146(2) 337-343).

[0254] Model parameter values ​​used in the simulations were sampled from a multivariate normal distribution with the parameter estimates centered and the covariance reflecting the uncertainty in the parameter estimates. Unexplained residual variability was included in the simulations. Simulation results were summarized in terms of geometric means and standard deviations of log values ​​(logs) and 95% prediction intervals.

[0255] Example 4: Modeling to determine dosage for Eosinophilic Granulomatosis with Polyangiitis (EGPA) The proposed dose and frequency of administration of 28Y042-7F11-1, 200 mg every 26 weeks, for the Phase 3 study of EGPA was identified using model-informed drug development (MIDD) principles. The dosing regimen of 28Y042-7F11-1 was selected to closely match the blood eosinophil pharmacology observed with mepolizumab in the pivotal Phase 3 study in the EGPA population throughout the treatment period. Further dose ranges of 28Y042-7F11-1 are not considered necessary prior to initiating the proposed Phase 3 program. Simulation analysis indicates that the additional benefit is limited in terms of blood eosinophil reduction above the proposed 200 mg SC dose of 28Y042-7F11-1 administered every 26 weeks; whereas, doses less than that are likely not effective because they do not match the desired blood eosinophil pharmacology.

[0256] Desired blood eosinophil pharmacology was reported by a pivotal phase 3 study with mepolizumab in EGPA, in which 32% of participants in the mepolizumab group achieved remission at both 36 and 48 weeks (vs. 3% in the placebo group). In this study, steady-state eosinophil reduction compared to baseline was 79% after mepolizumab 300 mg SC every 4 weeks. This reduction, converted to geometric mean (std log) blood eosinophil count at the end of the treatment period, corresponds to 0.038 (0.9398) GI / L in the cohort receiving mepolizumab 300 mg SC every 4 weeks. Simulation analysis indicates that additional benefit is limited in terms of blood eosinophil reduction above the proposed 28Y042-7F11-1 dosing regimen of 200 mg SC administered every 26 weeks. Furthermore, simulation analysis indicates that lower doses are likely to be ineffective because they are not compatible with the desired blood eosinophil pharmacology.

[0257] The dose and dosing frequency selection of 28Y042-7F11-1 targets the previous pharmacology of mepolizumab and is effective and rapid for the following reasons: · 28Y042-7F11-1 targets the same IL-5 epitope as mepolizumab and is therefore expected to provide similar clinical efficacy in the EGPA patient population selected for this study by establishing the same blood eosinophil reduction as mepolizumab through the same IL-5 neutralization. · The safety profile of IL-5 neutralization so far has been comparable to placebo.

[0258] The PK-blood eosinophil model used to support dose selection of 28Y042-7F11-1 is an updated model based on the indirect exposure-eosinophil model developed based on data from 16 mepolizumab studies that collected pharmacokinetic samples, blood eosinophil count measurements, and covariates in various eosinophil states and healthy subjects during mepolizumab clinical development. The model was parameterized for baseline blood eosinophils (KRO), clearance rate (KOUT), maximum inhibitory effect (Imax), concentration producing 50% of maximum inhibitory drug effect (IC50), and Hill coefficient (GAMA). Inter-subject variability was incorporated for baseline blood eosinophils and maximum drug effect using an exponential model. Measured baseline blood eosinophil count was a covariate for KRO and Imax. Disease was a covariate for KRO. The model was updated to reflect the longer half-life and enhanced potency of 28Y042-7F11-1 compared to mepolizumab while maintaining the same model structure. Model IC50 parameters, intersubject variability, and unexplained residual variability were estimated based on PK and eosinophil data from a single ascending dose Phase 1 study with 28Y042-7F11-1 in mild-to-severe asthma. The effect of baseline eosinophil levels on maximum achievable drug inhibitory response and on model-predicted baseline blood eosinophils was assumed to be the same between mepolizumab and 28Y042-7F11-1.

[0259] The PK-blood eosinophils simulation of 28Y042-7F11-1 was based on the PK model of 28Y042-7F11-1 developed based on data from a Phase 1 study of 28Y042-7F11-1 and an updated PK-blood eosinophils model. The simulated eosinophil levels at baseline reflected the actual values ​​(i.e., 0.177 GI / L) in the pivotal Phase 3 study of mepolizumab in EGPA and higher values ​​(i.e., 1.0 GI / L), which were more reflective of the disease burden when oral corticosteroids are tapered to a target oral corticosteroid dose of <4 mg / day over the course of treatment.

[0260] Model parameter values ​​used in the simulations were sampled from a multivariate normal distribution with the parameter estimates centered and the covariance reflecting the uncertainty in the parameter estimates. Unexplained residual variability was included in the simulations. Simulation results were summarized in terms of geometric means and standard deviations of log values ​​(logs) and 95% prediction intervals.

[0261] Example 5: Modeling to determine dosage for hypereosinophilic syndrome (HES) The proposed dose and frequency of administration of 28Y042-7F11-1, 200 mg every 26 weeks, for the HES phase 3 study was identified using model-informed drug development (MIDD) principles. The dosing regimen of 28Y042-7F11-1 was selected to closely match the blood eosinophil pharmacology observed with mepolizumab in the pivotal phase 3 study in the HES population throughout the treatment period. Further dose ranges of 28Y042-7F11-1 are not considered necessary prior to initiating the proposed phase 3 program. Simulation analysis shows that the additional benefit is limited in terms of blood eosinophil reduction above the proposed 200 mg SC dose of 28Y042-7F11-1 administered every 26 weeks; whereas, lower doses are likely not effective because they do not match the desired blood eosinophil pharmacology.

[0262] Desired blood eosinophil pharmacology was reported by a pivotal phase 3 study with mepolizumab in HES, where 50% fewer participants experienced HES relapse or withdrew from the study when treated with mepolizumab compared to placebo. In this study, steady-state eosinophil reduction compared to baseline was 95% after mepolizumab 300 mg SC every 4 weeks. This reduction was converted to geometric mean (std log) blood eosinophil count at the end of the treatment period, corresponding to 0.07 (1.299) GI / L in the cohort receiving mepolizumab 300 mg SC every 4 weeks. Simulation analysis indicates that the additional benefit is limited in terms of blood eosinophil reduction above the proposed 28Y042-7F11-1 dosing regimen of 200 mg SC administered every 26 weeks. Furthermore, simulation analysis indicates that lower doses are likely to be ineffective because they are not compatible with the desired blood eosinophil pharmacology.

[0263] The dose and dosing frequency selection of 28Y042-7F11-1 targets the previous pharmacology of mepolizumab and is effective and rapid for the following reasons: · 28Y042-7F11-1 targets the same IL-5 epitope as mepolizumab and is therefore expected to provide similar clinical efficacy in the HES patient population selected for this study by establishing the same blood eosinophil reduction as mepolizumab through the same IL-5 neutralization. · The safety profile of IL-5 neutralization so far has been comparable to placebo.

[0264] The PK-blood eosinophil model used to support dose selection of 28Y042-7F11-1 is an updated model based on the indirect exposure-eosinophil model developed based on data from 16 mepolizumab studies that collected pharmacokinetic samples, blood eosinophil count measurements, and covariates in various eosinophil states and healthy subjects during mepolizumab clinical development. The model was parameterized for baseline blood eosinophils (KRO), clearance rate (KOUT), maximum inhibitory effect (Imax), concentration producing 50% of maximum inhibitory drug effect (IC50), and Hill coefficient (GAMA). Inter-subject variability was incorporated for baseline blood eosinophils and maximum drug effect using an exponential model. Measured baseline blood eosinophil count was a covariate for KRO and Imax. Disease was a covariate for KRO. The model was updated to reflect the longer half-life and enhanced potency of 28Y042-7F11-1 compared to mepolizumab while maintaining the same model structure. Model IC50 parameters, intersubject variability, and unexplained residual variability were estimated based on PK and eosinophil data from a single ascending dose Phase 1 study with 28Y042-7F11-1 in mild-to-severe asthma. The effect of baseline eosinophil levels on maximum achievable drug inhibitory response and on model-predicted baseline blood eosinophils was assumed to be the same between mepolizumab and 28Y042-7F11-1.

[0265] The PK-blood eosinophils simulation of 28Y042-7F11-1 was based on the PK model of 28Y042-7F11-1 developed based on data from a Phase 1 study of 28Y042-7F11-1 and an updated PK-blood eosinophils model. The simulated eosinophils level at baseline reflected the actual value (i.e., 1.46 GI / L) from the pivotal Phase 3 study of mepolizumab in HES.

[0266] Model parameter values ​​used in the simulations were sampled from a multivariate normal distribution with the parameter estimates centered and the covariance reflecting the uncertainty in the parameter estimates. Unexplained residual variability was included in the simulations. Simulation results were summarized in terms of geometric means and standard deviations of log values ​​(logs) and 95% prediction intervals.

[0267] Example 6: Phase III Clinical Protocol - Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) This prospective example describes a planned Phase III clinical study.

[0268] This example is a randomized, double-blind, placebo-controlled, parallel-group Phase III study of depemoximab (100 mg) + standard of care (SoC) in approximately 250 adults with CRSwNP. The objective of this study is to evaluate the efficacy and safety of depemoximab (100 mg) + SoC administered subcutaneously (SC) by site staff via a prefilled safety syringe device every 6 months for 52 weeks. The efficacy of depemoximab will be assessed using two primary endpoints: change from baseline in total endoscopic nasal polyp (NP) score at week 52 and change from baseline in mean nasal obstruction VRS score from week 49 to week 52.

[0269] The study population consisted of adult participants (18 years of age) with CRSwNP. Additionally, participants must have an endoscopic NP score of at least 5 out of a maximum score of 8, with a minimum score of 2 for each nasal cavity. Participants must also have had prior treatment with systemic corticosteroids (SCS) any time within the past 2 years and / or have a medical contraindication / intolerance to SCS and / or have a documented history of previous surgery for NP at the time of the screening visit.

[0270] The study involves a 4-week run-in period followed by randomization to a 52-week treatment period as a double-blind, placebo-controlled phase. Total study duration is approximately 56 weeks. Randomization will be stratified based on country and the presence or absence of previous surgery for nasal polyps. Participants will be randomized in a 1:1 ratio to one of two treatment arms to receive depemoximab SC or placebo (both in addition to SoC) for a total of two doses (26 weeks apart).

[0271] Throughout the entire study period (run-in period + treatment period), participants receive SoC for CRSwNP. Depending on local practice, SoC includes INCS, saline nasal irrigation, occasional short courses of systemic corticosteroids, and / or antibiotics. Depending on local SoC / treatment, patients treated with INCS and / or LTRA should continue these treatments, without interruption or dose modification, for the duration of the study, if possible. If participants have not received INCS or LTRA before screening, they will be prohibited from initiating any INCS or LTRA during the study.

[0272] Key primary endpoints include: Change from baseline in total endoscopic NP score at week 52. Change from baseline in mean nasal obstruction VAS score during the period prior to and including Week 52 (4 weeks).

[0273] Important selection criteria include: Male or female, aged 18 years or older at the time of signing informed consent. Investigator-assessed endoscopic bilateral NP score of at least 5 out of a maximum score of 8 (minimum score for each nasal cavity was 2). Participants who had at least one of the following at visit 1: · Previous sinus surgery for NP removal; · history of use of systemic corticosteroids for the treatment of NP on at least 3 consecutive days within the past 2 years; Systemic corticosteroids are medically inappropriate or intolerable. Participants with severe NP symptoms, defined as symptoms of nasal congestion or blockage or nasal obstruction or rhinorrhea (runny nose) with moderate or severe severity (VRS score of 2 or 3) and loss of smell. Presence of symptoms of chronic rhinosinusitis, described by at least two distinct symptoms at least 12 weeks prior to the first visit, one of which must be either nasal discharge (anterior / posterior nasal drip) plus facial pain / pressure and / or decreased or lost sense of smell.

[0274] Example 7: Phase III Clinical Protocol - Eosinophilic Granulomatosis with Polyangiitis (EGPA) This prospective example describes a planned Phase III clinical study.

[0275] This is a 52-week randomized, double-blind, double-dummy, parallel-group, multicenter, non-inferiority study investigating the efficacy and safety of depemoximab (28Y042-7F11-1) compared with mepolizumab in adult participants with a history of relapsed or refractory EGPA and receiving stable corticosteroid therapy with or without stable immunosuppressive therapy.

[0276] Participants must have been on a stable dose of OCS, i.e., ≥ 7.5 mg / day prednisolone / prednisone (but not exceeding 50 mg / day), for at least 4 weeks prior to baseline (randomization / Visit 2). Participants receiving other immunosuppressive therapy must have been on a stable dose for at least 4 weeks prior to baseline (randomization / Visit 2) and must continue their immunosuppressive therapy for the duration of the study.

[0277] Participants will be randomly assigned in a 1:1 ratio to receive either 200 mg depemoximab SC given as 2 x 100 mg injections every 26 weeks as an add-on to SoC therapy, or 300 mg mepolizumab SC given every 4 weeks as an add-on to standard of care (SoC therapy).

[0278] Throughout the protocol, depemoximab treatment refers to 200 mg depemoximab SC administered every 26 weeks as an add-on to SoC therapy, and mepolizumab treatment refers to mepolizumab SC administered every 4 weeks as an add-on to SoC therapy.

[0279] The study consisted of a screening / run-in period (1–4 weeks), an intervention period (52 weeks), and a follow-up period (4 weeks).

[0280] Approximately 192 participants will be screened and 160 participants will be randomized (approximately 80 participants will be randomized to depemoximab 200 mg and approximately 80 participants will be randomized to mepolizumab 300 mg).

[0281] Intervention group and duration: Participants will receive either depemoximab 200 mg every 26 weeks (weeks 0 and 26) or mepolizumab 300 mg every 4 weeks, administered SC using a prefilled safety syringe (PFS), while continuing SoC EGPA therapy. Treatment duration will be 52 weeks, followed by a 4-week follow-up period without treatment. The final dose of depemoximab will be administered at week 26 and the final dose of mepolizumab will be administered at week 48.

[0282] Primary endpoint - Remission at both 36 and 52 weeks - Remission is defined as a Birmingham Vasculitis Activity Score (BVAS)=0 and an OCS dose ≤4mg / day.

[0283] Remission and relapse of EGPA have two components: Changes in symptoms Changes in OCS dosage

[0284] Important selection criteria include: - Age ≥ 18 years - Asthma plus eosinophilia (>1.0×109 / L and / or >10% white blood cells), plus a diagnosis of EGPA for at least 6 months based on a history or presence of at least two additional features of EGPA - History of recurrent or refractory disease Stable oral prednisolone dose ≥ 7.5 mg / day (but not exceeding 50 mg / day) for at least 4 weeks prior to baseline. If receiving IS therapy, it must be stable for 4 weeks prior to baseline and for the duration of the study.

[0285] Example 8: Phase III Clinical Protocol - Hypereosinophilic Syndrome (HES) This prospective example describes an intended Phase III clinical study: a 52-week randomized, placebo-controlled, double-blind, parallel-group, multicenter study of depemoximab (28Y042-7F11-1) in adults (>= 18 years) with uncontrolled HES receiving standard of care (SoC).

[0286] The study will recruit male and female patients with a confirmed diagnosis of HES and stable HES treatment for at least 4 weeks prior to randomization (visit 2). Eligible participants must have uncontrolled HES with a history of relapse (≥2 relapses in the past 12 months) and a blood eosinophil count ≥1,000 cells / μL during the screening period. A previous HES relapse is defined as documented HES-related clinical symptoms or worsening blood eosinophil count requiring intensification of treatment.

[0287] Participants will attend a screening visit (Visit 1) and will be required to sign a consent form before beginning screening activities. Participants who meet the inclusion and exclusion criteria will be randomized in a 2:1 ratio to receive depemoximab 200 mg (given as 2 × 100 mg injections) SC every 6 months (weeks 0 and 26) or placebo while continuing SoC HES therapy.

[0288] Management of participants during the study will be according to routine medical care, i.e. participants will be instructed to contact the investigator for evaluation or seek emergency treatment if necessary if they experience a worsening of symptoms according to usual practice. The investigator will assess the presence of HES relapse using the HES Core Assessment v2 (unscheduled relapse visit).

[0289] Approximately 120 participants will be randomized (approximately 80 participants will be randomized to depemoximab 200 mg and 40 participants will be randomized to placebo).

[0290] Participants will receive either depemoximab 200 mg or placebo every 6 months (at weeks 0 and 26) administered SC via a prefilled safety syringe while continuing SoC HES therapy. The study intervention duration is 52 weeks. The final dose of study intervention will be administered at week 26. For all participants, there will be an additional follow-up period of up to 4 weeks, i.e., up to 30 weeks after the last dose is administered.

[0291] Primary endpoint To determine the frequency of HES relapse over 52 weeks in participants with HES receiving depemoximab 200 mg SC plus SoC compared with placebo plus SoC every 26 weeks, regardless of whether they discontinued treatment for any reason and whether they received an alternative HES drug. To determine the frequency of HES relapses during the 52-week treatment period. Definition of HES relapse: HES-related clinical symptoms based on physician-documented changes in clinical signs / symptoms, requiring: Increased maintenance OCS dose Increased or additional cytotoxic and / or immunosuppressive HES therapy ≥2 courses of blinded active OCS during treatment (eosinophilic flare)

[0292] Important selection criteria include: Age ≥ 18 years, male and female Patients must have been diagnosed with HES prior to randomization: A blood eosinophil count >1,500 / μL on at least two occasions ≥1 month apart, with no discernible non-hematological secondary causes, and Signs or symptoms of organ damage and / or dysfunction that may be directly related to eosinophilia History of 2 or more HES relapses within 12 months prior to screening: Worsening clinical symptoms or blood eosinophil counts associated with HES necessitating the addition or intensification of OCS or cytotoxic / immunosuppressive therapy.

[0293] If there was at least one HES relapse within the past 12 months, the HES relapse must not be associated with a reduction in HES therapy in the 4 weeks prior to the relapse.

[0294] Example 9: Phase III Clinical Protocol - Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) This example is a predictive example and broadly describes a contemplated Phase III clinical study.

[0295] This example is a randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study investigating the efficacy and safety of 100 mg SC depemoximab (28Y042-7F11-1) in participants ≥12 years of age with CRSsNP and a baseline BEC of ≥300 cells / μL. The objective of this study is to evaluate the efficacy and safety of depemoximab 100 mg SC+SoC administered by on-site staff via a prefilled safety syringe device every 26 months for 52 weeks. The efficacy of depemoximab will be assessed using two primary endpoints: change from baseline in LMKCT score at week 52 and change from baseline in mean nasal obstruction VRS score by week 52.

[0296] The study population is likely to consist of adolescent (≥12-17 years) and adult (≥18 years) participants with CRSsNP. In addition, participants are likely to have a blood eosinophil count (BEC) ≥300 cells / μL at screening, an LMK score ≥8 on CT scan, and bilateral ethmoidal opacities prior to randomization. In addition, to be eligible, participants must have symptoms of anosmia and symptoms of rhinorrhea (anterior / post-nasal drip) of any severity with or without facial pain / pressure for at least 12 consecutive weeks prior to the first visit, be NC for at least 12 consecutive weeks prior to the first visit, and have an NC score ≥2 at the first visit (daily score) and second visit (weekly average score). Participants must also have an sTSS (NC, rhinorrhea, facial pain / pressure) score ≥5 at the first visit (daily score) and second visit (weekly average score). Participants must also have had prior treatment with SCS any time within the past 2 years, and / or have a medical contraindication / intolerance to SCS, and / or have a documented history of prior surgery for CRS at the time of the screening visit and have recurrent symptoms despite treatment with appropriate standard of care.Participants (excluding those residing in Japan) must have been treated with daily intranasal corticosteroids (INCS) [including intranasal liquid steroid irrigation / wash] for at least 8 weeks prior to screening.

[0297] The study will include a 4-week run-in period, followed by randomization to a 52-week treatment period as a double-blind, placebo-controlled phase, and a 4-week safety follow-up period. The total study duration, including follow-up, will be approximately 60 weeks. Randomization will be stratified based on the presence or absence of previous sinus surgery and country. Participants will be randomized in a 1:1 ratio to one of two treatment arms to receive depemoximab SC or placebo (both in addition to SoC) for a total of two sessions (26 weeks apart). Throughout the study period (run-in period + treatment period), participants will receive SoC for CRSsNP. Depending on local practice, SoC may include INCS, saline nasal irrigation, occasional short courses of systemic corticosteroids, and / or antibiotics.

[0298] The primary objective of this study is to evaluate the superiority of depemoximab plus SoC compared to placebo plus SoC in the following primary endpoints: a) Change in mean nasal congestion VRS score from baseline to week 52 b) Change from baseline to week 52 in sinus opacification assessed using the Lund Mackay score (LMK) score on CT scans.

[0299] array SEQ ID NO:1 - Full length heavy chain QVTLRESGPALVKPTQTLTLTCTVSGFSLTGSSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSGLLRLDYWGRG TLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK THTCPPCPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK SEQ ID NO:2 - full length light chain DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKL EIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ ID NO:3 - VH sequence QVTLRESGPALVKPTQTLTLTCTVSGFSLTGSSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMMDPVDTATYYCARDPPSGLLRLDYWGRGTLVTVSS SEQ ID NO:4 - VL sequence DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIKR SEQ ID NO:5-CDRH1 GSSVH SEQ ID NO:6 - CDRH2 VIWASGGTDYNSALMS SEQ ID NO:7-CDRH3 DPPSGLLRLDY SEQ ID NO:8 - CDRL1 KSSQSLLNSGNQKNYLA SEQ ID NO:9 - CDRL2 GASTRES SEQ ID NO:10 - CDRL3 QNVHSFPFT SEQ ID NO:11 - Human IL-5 (mature protein) IPTEIPTSALVKETLALLSTHRTLLIANETLRIPVPVHKNHQLCTEEIFQGIGTLESQTVQGGTVERLFKNLSLIKKYIDGQKKKCGEERRRVNQFLDYLQEFLGVMNTEWIES SEQ ID NO:12 - Human IL-5 receptor subunit alpha isoform 1 (mature protein) DLLPDEKISLLPPVNFTIKVTGLAQVLLQWKPNPDQEQRNVNLEYQVKINAPKEDDYETRITESKCVTILHKGFSASVRTILQNDHSLLASSWASAELHAPPGSPGTSIVNLTCTTNTTEDNYSRLRSYQVSLHCTWLVGTDAPEDTQYFLYYRYGSWTEECQEYSKDTLGRNIACWFPRTFILSKGRDWLAVLVNGSSK HSAIRPFDQLFALHAIDQINPPLNVTAEIEGTRLSIQWEKPVSAFPIHCFDYEVKIHNTRNGYLQIEKLMTNAFISIIDDLSKYDVQVRAAVSSMCREAGLWSEWSQPIYVGNDEHKPLREWFVIVIMATICFILLILSLICKICHLWIKLFPPIPAPKSNIKDLFVTTNYEKAGSSETEIEVICYIEKPGVETLEDSVF SEQ ID NO:13 - DNA encoding full length heavy chain with leader sequence SEQ ID NO:14 - DNA encoding full length light chain with leader sequence atgggctggtcctgcatcatcctgtttctggtggccaccgccaccggtgtgcacagcgacatcgtgatgacccagtctcccgattcactggccgtgagcctgggcgagagggccaccatcaactgcaagagcagccagagcctcctgaacagcggcaaccagaagaactacctggcctg gtaccagcagaaacccggccagcccccaagctgctgatctatggcgcctccaccagggagagcggcgtgccagacaggtttagcggcagcggcagcggcaccgacttcaccctgacaatcagcagcctgcaggccgaggacgtggccgtgtactactgccagaacgtccacagcttcc ccttcaccttcggcgggggaaccaagctggagatcaagcgtacggtggccgcccccagcgtgttcatcttcccccccagcgatgagcagctgaagagcggcaccgccagcgtggtgtgtctgctgaacaacttctacccccgggaggccaaggtgcagtggaaggtggacaatgccctg cagagcggcaacagccaggagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccctgaccctgagcaaggccgactacgagaagcacaaggtgtacgcctgtgaggtgacccaccagggcctgtccagccccgtgaccaagagcttcaaccggggcgagtgc SEQ ID NO:15 - DNA encoding the heavy chain variable region caggtgaccctgagggagagcggccccgccctggtgaagcccacacagaccctcactctgacctgcaccgtgagcggcttcagcctgaccggctctagcgtccactgggtgaggcagccccccggcaagggcctggagtggctgggcgtgatctgggcaagcggggggacggactacaactcggccctgatgagcaggctctccatcagcaaggacaccagccggaaccaggtggtgctgaccatgaccaacatggaccccgtggacaccgccacctattactgcgccagggaccctccctccggcctgctgaggctggactactggggcaggggaacactagtgaccgtgtccagc DNA encoding the light chain variable region of SEQ ID NO: 16 gacatcgtgatgacccagtctcccgattcactggccgtgagcctgggcgagagggccaccatcaactgcaagagcagccagagcctcctgaacagcggcaaccagaagaactacctggcctggtaccagcagaaacccggccagccccccaagctgctgatctatggcgcctccaccagggagagcggcgtgccagacaggtttagcggcagcggcagcggcaccgacttcaccctgacaatcagcagcctgcaggccgaggacgtggccgtgtactactgccagaacgtccacagcttccccttcaccttcggcgggggaaccaagctggagatcaagcgt DNA encoding the full-length heavy chain of SEQ ID NO: 17 SEQ ID NO:18 - DNA encoding full length light chain gacatcgtgatgacccagtctcccgattcactggccgtgagcctgggcgagagggccaccatcaactgcaagagcagccagagcctcctgaacagcggcaaccagaagaactacctggcctggtaccagcagaaacccggccagccccccaagctgctgatctat ggcgcctccaccagggagagcggcgtgccagacaggtttagcggcagcggcagcggcaccgacttcaccctgacaatcagcagcctgcaggccgaggacgtggccgtgtactactgccagaacgtccacagcttccccttcaccttcggcgggggaaccaagctg gagatcaagcgtacggtggccgcccccagcgtgttcatcttcccccccagcgatgagcagctgaagagcggcaccgccagcgtggtgtgtctgctgaacaacttctacccccgggaggccaaggtgcagtggaaggtggacaatgccctgcagagcggcaacagc caggagagcgtgaccgagcaggacagcaaggactccacctacagcctgagcagcaccctgaccctgagcaaggccgactacgagaagcacaaggtgtacgcctgtgaggtgacccaccagggcctgtccagccccgtgaccaagagcttcaaccggggcgagtgc SEQ ID NO:19 - Heavy chain FR4 sequence WGRGTLVTVSS

[0300] Now that the invention has been fully described, it will be apparent to those skilled in the art that many changes and modifications can be made therein without departing from the spirit or scope of the appended claims.

Claims

1. 1. A pharmaceutical composition comprising about 100 mg to about 300 mg of an antigen binding protein that binds IL-5, selected from EGPA, HES, CRSsNP, and CRSwNP, and a pharma- ceutically acceptable excipient, for use in treating an IL-5 mediated disease, the antigen-binding protein comprises a heavy chain variable region having a CDRH1 amino acid sequence shown in SEQ ID NO:5, a CDRH2 amino acid sequence shown in SEQ ID NO:6, and a CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having a CDRL1 amino acid sequence shown in SEQ ID NO:8, a CDRL2 amino acid sequence shown in SEQ ID NO:9, and a CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The pharmaceutical composition, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

2. 2. The pharmaceutical composition for use according to claim 1, comprising about 100 mg or about 200 mg of the antigen binding protein.

3. 3. The pharmaceutical composition for use according to claim 1 or claim 2, comprising about 100 mg of the antigen binding protein for use in treating CRSsNP or CRSwNP.

4. 3. A pharmaceutical composition for use according to claim 1 or claim 2, comprising about 200 mg of the antigen binding protein for use in the treatment of EGPA or HES.

5. 5. The pharmaceutical composition of claim 1, wherein the heavy chain variable region of the antigen binding protein further comprises a heavy chain FR4 amino acid sequence as shown in SEQ ID NO:

19.

6. The pharmaceutical composition according to any one of claims 1 to 5, wherein the heavy chain Fc domain is an IgG1 Fc domain.

7. 7. The pharmaceutical composition of any one of claims 1 to 6, wherein the antigen binding protein comprises a heavy chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:3 and a light chain variable region sequence having the amino acid sequence set forth in SEQ ID NO:

4.

8. 8. The pharmaceutical composition of any one of claims 1 to 7, wherein the antigen-binding protein is an antibody comprising a heavy chain having the amino acid sequence shown in SEQ ID NO:1 and a light chain having the amino acid sequence shown in SEQ ID NO:

2.

9. The pharmaceutical composition according to any one of claims 1 to 8, wherein the pharmaceutical composition is for subcutaneous administration.

10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the pharmaceutical composition is administered at a frequency of about once every six months.

11. The pharmaceutical composition of any one of claims 1 to 9, wherein the pharmaceutical composition is administered at a frequency of about once every 26 weeks (Q26W).

12. 5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is administered to treat HES or EGPA, and wherein two doses of 100 mg are administered at a frequency of about once every six months, e.g., separately or sequentially.

13. 5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is administered to treat HES or EGPA and is administered at two doses of 100 mg, administered at a frequency of about once every 26 weeks (Q26W).

14. The pharmaceutical composition according to any one of claims 1 to 13, wherein the pharmaceutical composition is administered to a human subject.

15. 15. The pharmaceutical composition of claim 14, wherein the human subject (a) has an absolute blood eosinophil count at initiation of treatment screening of (i) ≧200 or ≧300 eosinophil cells / μL of blood, or (ii) ≧150 eosinophil cells / μL of blood, or (iii) ≧100 eosinophil cells / μL of blood, and / or (b) has a blood eosinophil count of ≧300 eosinophils / μL of blood in the past 12 months.

16. 16. The pharmaceutical composition of any one of claims 1 to 15, wherein the pharmaceutical composition comprises an aqueous liquid formulation comprising the antigen binding protein and histidine, trehalose, arginine, EDTA and / or polysorbate 80 at a pH of about 6.

0.

17. An antigen binding protein that binds IL-5 for use in treating an IL-5 mediated disease selected from EGPA, HES, CRSsNP, and CRSwNP by administration to a subject at a dose of about 100 mg to about 300 mg about once every six months, the antigen-binding protein comprises a heavy chain variable region having a CDRH1 amino acid sequence shown in SEQ ID NO:5, a CDRH2 amino acid sequence shown in SEQ ID NO:6, and a CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having a CDRL1 amino acid sequence shown in SEQ ID NO:8, a CDRL2 amino acid sequence shown in SEQ ID NO:9, and a CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The antigen binding protein, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

18. 18. The antigen binding protein for use according to claim 17, wherein the IL5 mediated disease is selected from EGPA and HES and the dose is about 200 mg.

19. 19. An antigen-binding protein for use according to claim 18, wherein said administration of said dose of 200 mg is achieved by administering two doses of 100 mg, e.g. separately, sequentially or simultaneously.

20. An antigen binding protein for use in treating an IL-5 mediated disease selected from CRSsNP and CRSwNP by administration to a subject at a dose of about 100 mg about once every six months.

21. A method of treating an IL-5 mediated disease comprising administering to said patient an IL-5 mediated disease treatment agent selected from EGPA, HES, CRSsNP and CRSwNP, the method comprising administering to a human subject in need thereof an antigen binding protein that binds IL-5 in an amount of about 100 mg to about 300 mg about once every six months; the antigen-binding protein comprises a heavy chain variable region having a CDRH1 amino acid sequence shown in SEQ ID NO:5, a CDRH2 amino acid sequence shown in SEQ ID NO:6, and a CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having a CDRL1 amino acid sequence shown in SEQ ID NO:8, a CDRL2 amino acid sequence shown in SEQ ID NO:9, and a CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The method, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

22. 22. The method of claim 21, wherein the IL-5 mediated disease being treated is selected from EGPA and HES, and about 200 mg of the antigen binding protein is administered at a frequency of about once every six months.

23. 23. The method of claim 22, wherein administration of 200 mg of the antigen binding protein is achieved by administering two doses of 100 mg, e.g., separately, sequentially or simultaneously.

24. 22. The method of claim 21, wherein the IL-5 mediated disease being treated is selected from CRSsNP and CRSwNP, and about 100 mg of the antigen binding protein is administered at a frequency of about once every six months.

25. 23. The method of claim 22, wherein the IL-5 mediated disease is HES and the human subject has a screening blood eosinophil count of >1500 eosinophils / μL at the start of treatment, or the human subject is a patient already diagnosed with HES, already undergoing standard HES therapy, and having ≧1000 cells / μL.

26. 23. The method of claim 22, wherein the IL-5 mediated disease is relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis, EGPA.

27. 25. The method of claim 24, wherein (i) the IL-5 mediated disease is CRSsNP and the human subject has type 2 or eosinophilic endotype with elevated nasal eosinophil levels, e.g., the human subject has blood eosinophils of > 150 / μL, e.g., blood eosinophils of > 300 / μL, or (ii) the IL-5 mediated disease is CRSwNP and the human subject has an endoscopic NP score of at least 5 out of a maximum score of 8, with a minimum score of 2 in each nasal cavity.

28. 1. A method for reducing absolute blood eosinophil count in a subject, comprising: a) identifying a subject having a condition selected from the group consisting of EGPA, HES, CRSsNP, and CRSwNP; and b) administering to said subject an antigen binding protein that binds IL-5 in an amount of about 100 mg to about 300 mg about once every six months. thereby decreasing the absolute blood eosinophil count in said subject, the antigen-binding protein comprises a heavy chain variable region having a CDRH1 amino acid sequence shown in SEQ ID NO:5, a CDRH2 amino acid sequence shown in SEQ ID NO:6, and a CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having a CDRL1 amino acid sequence shown in SEQ ID NO:8, a CDRL2 amino acid sequence shown in SEQ ID NO:9, and a CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The method, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

29. For use in treating IL-5 mediated diseases selected from EGPA, HES, CRSsNP and CRSwNP; a) about 100 mg to about 300 mg of an antigen binding protein that binds IL-5, and b) Pharmaceutically acceptable excipients A prefilled syringe comprising: the antigen-binding protein comprises a heavy chain variable region having a CDRH1 amino acid sequence shown in SEQ ID NO:5, a CDRH2 amino acid sequence shown in SEQ ID NO:6, and a CDRH3 amino acid sequence shown in SEQ ID NO:7, and a light chain variable region having a CDRL1 amino acid sequence shown in SEQ ID NO:8, a CDRL2 amino acid sequence shown in SEQ ID NO:9, and a CDRL3 amino acid sequence shown in SEQ ID NO:10, and comprises a heavy chain Fc domain having a tyrosine residue at position 252, a threonine residue at position 254, and a glutamic acid residue at position 256; The pre-filled syringe, wherein the amino terminus of the heavy chain Fc domain is linked to the carboxy terminus of the heavy chain variable region.

30. 30. The pre-filled syringe of claim 29, wherein the pre-filled syringe comprises about 100 mg of the antigen binding protein.

31. 30. The pre-filled syringe of claim 29, wherein the pre-filled syringe contains about 200 mg of the antigen binding protein.

32. The pre-filled syringe of any one of claims 29 to 31, comprising an aqueous liquid formulation of about pH 6.0 comprising the antigen-binding protein and histidine, trehalose, arginine, EDTA and / or polysorbate 80.

33. A pre-filled syringe according to any one of claims 29 to 32 for use in the treatment of IL-5 mediated diseases, such as EGPA, HES, CRSsNP and CRSwNP.

34. 34. The pre-filled syringe according to any one of claims 29 to 33, provided in a safety syringe device (SSD) or an auto-injector.